- ,
r - : /18421'0
36 -
GMP EU
1-6 99%
s
-
,
,
peumoiae,
Streptococcus
Haemophilus ifluezae, Haemophilus paraifluezae, Mycoplasma peumoiae,
Chlamydia peumoiae.
Eterococcus
faecalis,
Eterococcus
cloacae,
lebsiella
peumoiae,
Poteus
mirabllis,
,
Escherichia coli, Klebsiella peumoiae, Poteus mirabllis ,
Escherichia coli, .
uu vn: nn - 750r / 500r / 25r, lil'lcepw-5-Nll1
(5 116
388 ti ti nn
n il
BMS Siemens
no n
n il)
www.higlance.ru
N!! 212
11 11
: -001514
~!J
16/02/2012
, , .);
(
, ,
);
(
,
,
).
Jl(f.l\ile . G
4J!!'"' '
: ; ; Lifel
:
1 3
, .
, , .
./:
E-mail:
123007,
400
_ _ _ _ _ _ 325
13 , .3
(495) 940-33-96; 940-33-97; 940-33- 98.
rus@higlace.ru
: www.higlace.ru .
1
""'anav
"~naaLI
.. , .. , ..
2012
615.33
52.82
72
72
/ . . ,
. , .. .
.: ,
2012. - 232
.: .
ISBN 978-5-98811-220-4
: ,
;
;
;
;
, ,
;
.
, , ,
,
, , , .
615.33
52.82
,
ISBN 978-S-98811-220-4
2012
2012
, ,
, . .
, .:
.
..
..
..
: 70 100
1
/
16
16.07.2012.
. .
" ".
1000 .
.No 10925
!
:
:
:
+ 7( 499)324-93-29
+ 7( 495 )981-91-03
+7(916)320-01-55
www.medprit.ru
ISBN
S-988-220-
~SPAUDA
. 60,
LT-05120 ,
www.spauda.com
9 785988
11
2204
................................................................................. 6
.................................................................................. 7
1.
.................................
1.1.
................................................... 9
1.2. .... 13
1.2.1. ............................................ 13
1.2.2. .................... 17
1.2.3. ............................................................. 20
1.2.4. .................... 24
.......................................................................... 32
2. -:
......................................... 38
2.1.
................. 39
.11 3.
.......................................................................... 52
-: ...................................... 56
( .., .., 0..)
3.1.
3.2.
....................................
3.3.
3.4.
56
................................................. 61
............ 63
........................................ 69
.......................................................................... 76
.11 4. -: ................. 79
( .., ..)
4.1.
4.2.
.................................... 79
................................................. 84
.......................................................................... 87
5. ........................................ 90
( .., ..)
5.1.
5.2.
.................................... 90
......................................... 95
5.3. ................................................. 97
.......................................................................... 99
6.
....................................... 103
{ .., ..)
6.1.
6.1.
6.3.
................................... 103
............. " .............. " .. ". " .......... 107
7.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
......................................................................... 111
......................................................................... 115
( .., ..)
7.1.
................................... 115
1.1. ................................................ 118
......................................................................... 121
n 8.
................................................ 123
( .., ..)
8.1.
8.2.
................................... 123
................................................ 127
......................................................................... 129
n 9.
............................................................ 131
( ." .., ..)
9.1.
9.1.
................................... 131
.. " ............. " ............. " ...... 135
9.3.
................................................ 137
......................................................................... 140
10.
................................. 144
( ..)
10.1.
10.1.
................................... 144
........................................ 149
10.3. ................................................ 153
......................................................................... 164
11.
................................................................. 169
( ." ..)
11.1.
11.2.
................................... 169
................................................ 171
.3.
........................................... 174
......................................................................... 178
11. ..................................................................... 181
( .., ." .., ..)
12.1.
...................................
11.2.
181
............................................... 186
11.3. ................. 188
12.4. ............... " 191
12..S.
.............................................. 192
......................................................................... 196
................................................................. 200
13.1.
.................................. 200
13.1. ............................................... 203
........................................................................ 205
14.
.......................................... 208
( ." ..)
14.1.
14.1.
.................................. 208
................................................ 216
......................................................................... 221
............................................................................... 225
, .
, ,
, -
, ,
, , .
CD
N-
iMOS
LAK
--
:-:
( )
NK
Tctl
:: -
Th
TLR
Treg
ll-n
: :
NFB
/J-:
HLA
&
.. , .. , ..
[1, 12].
, ,
, ,
, ,
,
.
, ,
10-15
,
. ..
.
(14],
(10],
..
(3],
..
.. , .
. Begogne-Berezin
[1],
, -
,
.
1.1.
(89].
, , ,
, ..
, .. , ..
.. , ..
[4],
[5], .
[8], J. Calvo, L. Martinez-Martinez [32],
D.M. Livermore (75], . Yokota [125].
"..,,,,,..1.11"1.
(r)
fl-: ,
, ,
; rn,
,
, ,
, ,
, ,
1.
C):n~~
~.~~
~~111681~11
+
+
+
I::::~"::::~'.:.:::1
""
,
n,
4111
1.
1.
/3-,
(.
, . .
2),
. ,
( ) , ,
4118
, ,
,
, ,
11.
1.
,
::
, , , ,
. .
(62, 110].
,
,
, , ,
,
11 .
.3.
r -
[13), . Briones,
C.I. Colino, J.M. Lanao [30), N.A. Calone
. [33], C.G. Gemmel [42], W.L. Hand,
N.L. King-Thompson [49), .. Labro [67).
..
();
, . .
, .
[4, 5, 8).
, ,
, .. ,
.. , ..
, ..
, . . .
(7J,
[9],
[6],
[2],
..
..
. , ..
, ..
[11),
..
, -
1.1.1.
..
( ,
,
).
,
.
.
, ,
, ,
G,
,
,
.
,
,
, ,
(,
),
()
HLA-D
HLA-D
, :
[106],
[73]
[115],
, -.
,
. ,
, :
[123],
[104],
[50]
[72],
. , -
, ,
, . .
HLA-D
(.
4).
_,,
__.
'
\.,
+ HLA-D
. 4. :
IgG,
(Thl).
, ,
- (-)
- (-),
-/J
- 1-
[28].
(,
. (
, ),
, , .)
[28].
: , ,
, .
- -
, , ll-
. ,
TLR
(TLR),
, ,
[80,
. ,
103],
-2 (-2)
(.
-.
5).
, ,
[47, 94).
, , ,
, , ,
-)
[28].
HLA-D
, .
. , ,
[63, 79].
1.2.1.
. -
.---
,
,
,
[..\)
5.
, ,
6.
. 6.
. ,
, ,
.
(
[77, 112].
).
(NK),
. ,
-:
[61].
()
CD
(Claster differentiation),
:,
(, ,
.) -
-,
IgE
(; ,
. ,
.). -,
: -
(Th)
(Tctl).
(-2, -4, -,
-1/3 .) - ,
1.1..
, , ,
: (.
7).
-, -, -
11
-
:
(Thl)
N-
CD5+
CD56
dim
><
2i
2 t3
:s:
"!i
t:;
!>,
::i:: ::;;
"' "'
8-g~
~~[
"'
:s:
a:ix
>.. 1
><
::i:: 1
:-
..
'- "'
~ 2-
. ::r ::i::
~:s:
::;;
:s: :::
:?1 ~
~~
'-
!2- @1
(.)
~~
: :
"'
:r 1
~5
!f
::i::
:r "'~
~~:s:
~~
::
>:S:
:;;
:-
"'
:s: ' :s:
:::
::rb ffi5'8
~~::: sr::i::
~~
"'
~~
:s: (5 (.) :s:
"'~
:: :
f :! ~
:-IO
m ::i::
~i:;;
..::!!
:s:
s:
::!!
>-
~~
:::..,
s..8.
si
"'
~
s
:;;
~ :::
:r
>:s:
:;; :::
:;; Q)
:s: 2-
.~~
"' :s:
:::
l~
i
~
"' "'~" ::!i>< "' e~s
80
1 :
~~
:s:"' ....
....
Q)
~
:s:
::i:: :::
~
:;; :s:
::;; :::
s .
"'"'
8~
:s;
Q>
>.. >..
$.."'
u::r
~~~~
::r
~~~
t-t=..
:- !i2 ~
g ~ ~~
"'::i::
!>,
~~:r~
::: r:o ::
:s:;: :s:~
:::
::i::
:s:
~ :r
1-
65~
::i:: <D
~ ~ :s:
><
:s:
"'
:::J--""
!@
&.
::r "'8
. ~
::i::
"'
t:;
~ ::r
:s:
1-
if i'8
:;;
"'
~~
.J: : !;;:
::i:: 1
"'
::~ :-~
2
i !
>..
~~
lig
::i::
::r
::i::
:s: m ~
"'\i) ~
~ 01
!J!
i~
g \i)
::i:: ~ !2
~b~:!S
~~~~
~ -& t;"'
::r
:s:
>'::i::
--.
sx~
ffi
-o:sCP
:r8_
:::~& ~~:::
:;;"" ::t:
~
~i~
::t:
~s: .i
r:::
:::
. 7. : , ,
(Th2)
(Thl 7),
,
.
(Treg). -
(Tctl)
, , ,
, ,
, ,
(-)
IgM,
. -
(-4,
[20).
-6 .) -
: -
- '
, ,
[52, 84];
(,
-.
(),
. .)
[56, 87,
111, 121];
. ,
[44, 45];
-,
[31, 71];
[26].
[19, 98];
-.
, .
[117].
- :
, . .
lll
[28].
).
N-
in vitro
-lll
IgG,
lll
lll
-,
(-2 .)
in vivo
(LAK).
lll
[119, 120].
NK-
, -
, . .
. N-
, ,
-,
N-
[28].
N-
,
HLA I
(lll
) .
lll
HLA I
, ,
-lll
[29].
NK
, N-
. ,
1.2.4.
(.
8),
, ,
. ,
(3),
, ,
, , .
, -
. ,
14
>'
q..
r
S-
423
42
.:;" :'';
--
'
.=
........ ~
'-..
"
/.
~ ~(
\ 6
f+csa {?
p-D
cs\.cs /
=~-
'\,
5'J-
"-
5-
q..
r
8.
Cl
. ,
- (. .
8).
[82].
. ,
, .
Strepfococcus pneumoniae,
idis. -
r,
r,
5-8
Neisseria.
, r
[82].
. l-
. ,
) ,
. ,
3.
, , )
, .
3.
3.
[90].
[34,
96],
[85].
, ,
[62],
[39]
[84].
, .
()
, . .
-, -, -1/1, -2, -
4,
.
(-
- (.
-
9).
, -
Tctl
57::
.....;;;;;;;;~~...-~
,
;;;;;;;;;;;;;;;;;;;tlJJ
N-
__.,..ai.
"
. 9.
:. ,
:,
N-
() .
- -
Thl (CD4), NK
-2
. -2
Thl
-2
CD4 (ThO)
Th2,
Tctl
Tctl.
NK:
N.
N- L-.
-1,8
, (
) .
. -1,8
- .
-,
-1,8
,
(-),
-6
-1,8
()
(Treg),
-1 -lr,
-2
-.
(CD4/CD8),
Thl,
-1.
-6
-,
Tctl,
, ,
-3,
[72].
, -,
. -8
, ,
: ,
-1
, N-,
-lr
-;
-6.
-8
, ,
()
(-1, -6),
[28].
, ,
, ,
-2.
-2
, -
11
-10,
- -2
[81, 25]
-10.
, ,
[25, 92].
-,
[86].
-1, -6
-10,
, ,
[25),
[113)
- [113].
-
[28].
IgE.
[24, 46],
-/J
[92],
[31, 88, 116]
-,
2.
IgD
[31].
-,
-1,8
[109, 126],
2.
-6, -8
11 111,
/n
t1.11
lgD
fgM
lgG
lg
0,03
1,5
13,5
++++
++
nQ
1!4
lgE
FceRI, PcyRll
10-5
+++
1 n!'
~-
OTl\leT
nr
IgM
IgA
: -
IgM
, , ,
-,
--
, -
, -
IgM
IgE
, , -
30
5-10 / .
IgG .
,
- ,
1 .,
IgG
80
IgG
,
,
( , ,
, )
.
IgE
Ig-
,
.
Ig-
,
IgA
IgA
. .
IgE,
IgA.
IgA. -
,
-;
1.
.. . : -,
2.
. . .. ,
2009.
..
. .: . .
.. , .. , ..
. .: -,
.
[28].
S. pneumoniae
IgA
(26].
4.
5.
[13],
(52, 53, 74];
[55, 70, 124].
,
..
.. . : ,
2007.
..
2003.
." ..
, . .:
,
7.
2000.
..
. .: -,
2003.
8.
.
. .: ,
9.
.. . .: ,
6.
..
98];
2002: 146-161.
. .
. . influenzae,
..
. .: ,
10.
1999.
..
2005.
..
. :
:.
11.
2002.
." ..
13.
2000; 1: 61-64.
..
- : . .. "
:,
1999; 1: 31-36.
." ..,
.. . .: ,
12.
. . .
- . "
14.
1992.
..
: . .:
2006 .
15.
..
.:
1999.
16. Abbas .., Lichfman .., Pillai 5. Cellula and Molecular immunology. Shiv. Pillai,
6th edn., 2007.
17. Anfoniades C.G., Berry .., Davies . . ef
/. Reduced monocyte HLA-DR expression:
novel iomarker of disease severity and
outcome in acetaminophen-induced acute
liver failure. Hepatology 2006; 44: 34-43.
18. Anfoniades C.G., Berry .., Wendon J.A.,
Vergani D. The importance of immune dysfunction in determining outcome in acute
liver failure. J. Hepatol. 2008; 49: 845-861.
19. Anfunez ., Fernandez ., Blanca-Lopez N.
ef /. IgE antibodies to betalactams: relationship between the triggering hapten and
the specificity of the immune response. Immediate hypersensitivity reactions to penicillins and other betalactams. Curr. Pharm.
Des. 2006; 12: 3327-3333.
20. Arnaiz-Villena ., i ., RodriguezGallego . Human T-cell activation deficiencies. Immunol. Today 1992; 13: 184-189.
21. Arning ., Kliche .., Heer-5onderhoff
.., Wehmeier . Infusion-related toxicity of three different amphotericin formulations and its relation to cytokine plasma
levels. Mycoses 1995; 38: 459-465.
22. Baginski ., Czub J., 5ternal . Interaction
of amphotericin and its selected derivatives with membranes: molecular modeling
studies. Chem. Rec. 2006; 6: 320-332.
23. Baginski ., 5fernal ., z 1., Borowski .
Molecular modelling of membrane activity
of amphotericin , polyene macrolide antifungal antiblotic. Acta Biochim. Pol. 2005;
52: 655-658.
24. Bauhofer ., Huffel ., Lorenz W. ef /. Differential effects of antiblotics in comblnation
with G-CSF on survival and polymorphonuclear granulocyte cell functions in septic
rats. Infect. Dis. 2008; 8: 55.
25. Bendtzen ., Diamanf ., Faber V. Fusidic acid, an immunosuppressive drug with
functions similar to cyclosporin . Cytokine
1990; 2: 423-429.
26. Benjamini ., 5unshine G., Leskowifz 5. Immunology, short course. New York: WILEY-LISS, 1996.
11
53. Henry-Toulme N., Sarfhou ., Bolard J. Early membrane potential and cytoplasmic calcium changes during mitogenic stimulation
of WEHI 231 cell line polyene antiiotics,
lipopolysaccharide and anti-immunoglobulin. Biochim. Biophys. Acta. 1990; 1051: 285292.
54. Henry-Toulme N., Sarfhou ., SemanM., Bolard J. Membrane effects of the polyene antiiotic amphotericin and of some of its deriva tives on lymphocytes. Mol. Cell Biochem.
1989; 91: 39-44.
55. lbrahim M.S., Maged Z.A., Haron . ef /.
Antiiotics and immunity: effects of antiblotics on natural killer, antibody dependent
cell-mediated cytotoxicity and antibody
production. Chemioterapia 1987; 6: 426-430.
56. lbrahim M.S., Maged Z.A., Haron . ef /.
Antiblotics and immunity: effects of antiblotics on mitogen responsiveness of lymphocytes and interleukin-2 production. Chemioterapia 1988; 7: 369-372.
57. Kadota J., Mizunoe S., Kishi . ef /. Antiiotic-induced apoptosis in human activated
peripheral lymphocytes. Int. J. Antimicrob.
Agents 2005; 25: 216-220.
58. Kalish R.S., Koujak S. Minocycline inhiblts
antigen processing for presentation to human cells: additive inhiition with chloroquine at therapeutic concentrations. Clin
Immunol. 2004; 113: 270-277.
59. .., Balistreri F.J., Torney H.L. beta-Lactam antiblotic modulation of murine
neutrophil cytokinesis. Immunopharmacol.
Immunotoxicol. 1992; 14: 797-811.
60. Kodama N., Yamada ., Nanba . Addition
of Maitake D-fraction reduces the effective
dosage of vancomycin for the treatment of
Listeria-infected mice. Jpn. J. Pharmacol.
2001; 87: 327-332.
61. Kohyama ., Takizawa ., Kawasaki S. et /.
Fourteen-member macrolides inhiblt interleukin-8 release human eosinophils from
atopic donors. Antimicrob. Agents Chemother. 1999; 43: 907-911.
62. Krisfian S.A., immer .., Liu G. . et /.
Impairment of innate immune killing mechanisms bacteriostatic antiiotics. FASEB
J. 2007; 21: 1107-1116.
63.
11
97. Roitf /., Brosfoff J., Mail . Immunology. Edinburgh, London, New York: Harcourt Publishes Ltd., 2001.
98. Romano ., Bousquet-Rouanef L., Vio/a .
ef /. Benzylpenicillin skin testing is still important in diagnosing immediate hypersensitivity reactions to penicillins. Allergy 2009;
64: 249-253.
99. Roszkowski W., H.L., Roszkowski . et /.
Antiblotics and immunomodulation: effects
of cefotaxime, amikacin, mezlocillin, piperacillin and clindamycin. Med. Microblol. Immunol. 1985; 173: 279-289.
100.Sahin G., Akay .., Kus . ef /. Effects of
immunosuppressive drugs on platelet aggregation and solue P-selectin levels in renal transplant patients. Ren. Fail. 2009; 31:
111-117.
101.Sandler ., Ekokoski ., Lindstedf .. ef /.
.,
Mafsuura
.,
Saifo S. et
/.
116. Torfoss
.,
Hoiby
..,
Holfe
.,
Kva/oy 5.
Penicillin and aminoglycoside in febrile neutropenia. Tidsskr. Nor. Laegeforen. 2008; 128:
2738-2740.
117. Van den Bogerf
.,
Me/is
."
Kroon
..
118. Van
ci
-:
.. , . , ..
/3-
(/3-)
,
Strepfococ-
/3- . /3-
cus,
/3-
, . .
[8, 9, 12].
( G,
/3-.
). /3-
/3-
200
/3-
/3-
/3- ,
[5, 8, 31].
, -
[58].
::
/3-,
/3-:
3.
[9]
(),
au111"1.i1a
(},
()
nn
/)-
nnn1:
lin: ,
[5].
nn: n,
nn
1.1.
nn:nnn,n
:
n/ (n), n
n/, /n
, nn/
, ,
Enterococcus spp.
spp.,
[27, 39].
muffocida
ducreyi,
Neisseria
(J-.
(.
3).
[11].
/3-
terobacteriaceae
Salmonella spp.
().
/)-.
60-90 /),
(.
.
, Streptococcus spp.,
Staphylococcus spp., Bacil/us spp., ,
Haemophilus spp.,
pylori,
{3-
j-
[8, 11].
/,
{3-
[8, 11].
Klebdiversus,
fragilis,
{3-
,
.
siella spp.,
vu/garis,
{3-: ,
, .
co/i,
{3-
,
aeruginosa,
(5. maltophilia).
(-
S. pneumoniae),
[5, 8].
j-
, .
Enterobacteriaceae,
( )
Enterobacteriaceae
( Klebsiella spp., . vulgaris, . diversus), . aeruginosa
/3-,
[5, 8, 12].
10.
4
.
.
Streptococcus spp.
Staphylococcus spp.
Enterococcus faecalis
Peptostreptococcus spp.
:
Neisseria spp.
. catarrhalis
:
Listeria spp.
. diphtheriae
Bacillus spp.
. rhusiopathyae
:
Clostridium spp.
Actinomyces spp.
:
Borrelia spp.
Leptospira spp.
Treponema spp.
Rickettsia spp.
Coxiella spp.
Orientia spp.
:
. pylori
. diversus
. fragilis
:
i----+-{
Haemophllus influenzae
Enterobactericeae:
E.coli
Salmonella spp.
Shigella spp.
Proteus spp.
Klebsiella spp.
:
. aeruginosa
10.
, ,
, ,
. /:1- (
, )
75 % [8].
, .
[8].
[11, 13].
4.
[8, 28],
/, /;
n11
0,5 4
2-6 4 ; 4-12 4 ;
- 50 %; - 40 %;
- 20 % [9, 12]
- n
-
faecalis;
[25),
[32],
pylori [35];
, 11, rn ;
n, wrenne1; , 1 ,
1Dv -:;~
[9, 12]
, , :
, , :
,
, :
. :
[47].
/3-
: ,
:
, ,
. :
80-
: ,
/3- ,
,
[3].
, ,
[40],
[38],
11.
/3-
: : -
. 11. -
, . .
,
[54].
/J-
-
/J-
), ,
[11, 65].
()
/J-),
Escherichia coli
12).
(.
, -, ,
/J-
, -,
N-,
. .
/J- -
,_ _____
t
1
- - - - - - - - - - - - -
------~
+-+-------+---+--+-+---11-+,
,__________
..____
__j
11. /:J-
, ,
-8 -1
(8, 71].
, ,
us
lococcus aureus.
,
Staphy-
5. aure-
[45].
, ,
24
.: , .: -8
-1
(-1)
, -
, ,
.:
N-
, -
[7].
. ,
5. pneu-
moniae -
- ( - )
(.
1
/
6-
-1/3 .
13).
, -1,8
13
[67],
[52].
5. pneumoniae
TLR2
-8-
TLR2.
HeLa.
[6].
-8-
cTLR2
13. ,
, /3-
LR2-
-4.
, -
. -1/3, -2, -
5,
h2-
Thl-
-13 -, -10.
. . ,
, -
[51].
. /
vitro
- ( -1/3 -)
0,5
500
CD54
-4- -13-
, ,
[1].
, /)-
/3- ,
[43, 57],
, . . /)-
, ,
[18].
56, 70].
[16,
/3-.
R.
/3-,
, - -
/3-
[15]. ,
, Ig-
/3-
1.4.
(),
,
/3-,
(). -
IgE
[13, 63].
- .
(),
/3- ,
Ig-
()
Thl-
11
Ig-
[30].
h2-
( ),
. -
/3-
, h2-
Ig- ,
[4, 10].
Thl-
N-,
NK,
, - -.
L.J. Moore
[51]
1.S.
- ,
(NO)
.
,
->
: ,
,
,
.
14.
; ,
(. .
14).
,
-,
G, D
[16].
in vitro
( ,
) ,
[42].
CD8
).
in vivo
[19].
-2
- in
L-
vitro
/3-
[59].
!:
-,
! -8~
-1
-1 ~. -2,
-5, -13,
- 1
+
Th1-
h2-
"'
,
,
lg-
(-
- )
'4. 14.
[21].
IgA,
, -/31
( )
[6, 24].
IgA,
15
IgG
IgA ,
IgA .
, ,
NK-
[23],
- -,
, ,
[33, 36,
-:
in vifro
/j-
64, 69].
[13, 34,
, /j-:
: .
in
vifro
G / ,
Streptococcus,
64,5 %
57,9 % 3.
: /3-
/3-,
[62].
92,8 %
()
-:
-:
: (), :
. /3-
, /j-,
. , :
, -
[46].
NK, ),
, ,
[64].
(lg-),
.
, ,
8.
9.
..
: ,
10.
..
2005.
..
: . .:
12.
..
..
CD45
. .... . . . ,
1999.
3.
.., ..,
.. .
(
):
. .,
4.
1988.
.., ..,
.., .. ,
. .: ',
5.
2001.
.., ..,
.., ..
/3-:
.
. . .
.
6.
.., .., ..
.
. . .
7.
.., ..,
..
/3-
. . .
11
..,
2006.
..
1. .., ..,
2007: 69-76.
. .: ,
11.
2.
2005; 7(1):
.., ..,
() -
92-96.
. . .
IgE-ooc-
.. /3-
in vitro.
2001; 64(4): 68-72.
30. Horfon " Wesfon S.D" Hewiff C.R. Allergy to antiiotics: T-cell recognition of amoxicillin is HLA-DR restricted and does not require antigen processing. Allergy 1998; 53:
83-88.
31. Jacobs M.R. Optimisation of antimicroial
therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microiol.
Infect. 2001; 7: 589-596.
32. Jansisyanont " Sessirisombat S" 5asfravaha
" Bamroong . Antiiotic prophylaxis for
orthognathic surgery: prospective, comparative, randomized study between amoxicillin-clavulanic acid and penicillin. J. Med.
Assoc. Thai. 2008; 91: 1726-1731.
33. Kadota J" Mizunoe S" Kishi . ef /. Antiiotic-induced apoptosis in human activated
periphera] lymphocytes. Int. J. Antimicrob.
Agents 2005; 25: 216-220.
34. Kerdine S" Pallardy " Lamanefre 5. ef /.
Interleukin-10 and interleukin-4 have simiJar effects on hapten-specific primary antibody responses to penicillin in vivo. Eur. J.
Immunol. 1996; 26: 2890-2894.
35. Kim N" Park 5." 5 G.S. ef /. Lafutidine
versus lansoprazole in comination with clarithromycin and amoxicillin for one versus two
weeks for Helicobacter pylori eradication in
Korea. Helicobacter 2008; 13: 542-549.
36. " Pichler W.J" de Weck A.L.
cell reactivity to penicillin: phenotypic analysis of in vitro activated cell subsets. J. Allergy Clin. Immunol. 1986; 78: 645-652.
37. Kazi " Hill R" Long .. ef /. Novel N-thiolated beta-lactam antiiotics selectively induce apoptosis in human tumor and transformed, but not normal or nontransformed.
Biochem. Pharmacol. 2004; 67: 365-374.
38. . " Balisfreri F.J" Torney H.L. beta-Lactam antiblotic modulation of murine
neutrophil cytokinesis. Immunopharmacol
Immunotoxicol. 1992; 14: 797-811.
39. " Hare " Feng L. ef /. Detection of
beta-lactamase reporter gene expression
flow cytometry. Cytometry 2003; 51: 68-78.
40. Labro . . Interference of Antibacterial
Agents with Phagocyte Functions: Immunomodulation or Immuno-Fairy Tales?
Clin. Microblol. Rev. 2000; 13: 615-650.
11
-:
.. , . , ..
/)-
/)-,
[6,
9, 24].
/)-
,
(.
5).
-
/)-,
.
III
Enterobacteriaceae
Pseudomo-
5.
1n
11
111 nn
IV n
Qn
()
()
n
n
()
"fi nn
()
nas,
2009 .
[8, 9, 25].
(;
1 2
:.
Pharmaceutica N.V.,
),
Janssen
/3-
/3-
IV
[21].
. -
[5, 22].
in vitro,
[7, 9, 24].
III (
) (
),
Haemophilus influenzae.
)
, -2,
[26].
Bacteroides, III IV -
Pseudomonas aeruginosa
[6, 9].
V
Enterobacteriaceae
S. aureus
, S. pneumoniae, . faecalis, ,
-
,
S. aureus.
influenzae,
/3-
- ), . aeruginosa.
I-IV
15.
6.
Staphylococcus aureus
Streptococcus pyogenes
Streptococcus pneumoniae
:
. catarrhalis
Neisseria spp.
: Prevotella spp.
Porphyromonas spp.
:
Haemophilus spp.
E.coli
Proteus spp.
lebsiella spp.
Enterobacter spp.
Serracia spp.
~~:~~~
. aeruginosa
11. 15.
6.
11
n1 1 ;
0,4 \-2 ;
........ 22-27 %; n - 50 %;
- 65 % (9J
l{r , wrenne, ,
nw1-1
(9, 48)
n /; 0,5 2 60-~
0,5 8 120-
()
(3, 14)
S. aureus n -
), . aeruginosa [,
14, 26)
[22, 54]
[36].
III
3.2.
IV ,
1
. ,
5. pneumoniae
influenzae,
(5
80- ,
[51].
12- ) [18],
in vitro
in vivo,
[36].
[23].
/J-,
(.
[25].
16).
[2, 7,
1980-
30, 52].
, ,
, ,
[35].
[3, 54].
[52].
[53].
FMPL
. 16.
FMPL - ---.
. -
[10-12].
1)
FMLP -
[27].
2)
-,
; ,
()
2 .
coli,
[50].
vifro ,
Rouveix,
F. Chau [44],
11
[6].
, Ig-
III
. -
[24].
[45].
, ,
- ,
[13].
-6
-, . .
. ,
. -
, . .
17).
(.
- -1 .
(-, -6,
[13].
-2)
[10-12].
, ,
. ,
[40-42],
(LTB 4 )
[46].
R3,
11
1 n
11 n
111 n
111 n
111 n
111 n
!!!!!!!!!!!!!!!!!~ ,
.
MIP -
17.
!! !! !! !!
[31,
39, 43].
, -
).
() ..
[7].
, : ,
0,1%
7.
: ,
96-98 %,
. .
2-4 /.
60
[31, 33].
I :
40
1,5-5 %,
-1,5-14%
-:
(LTB 4 ) [46].
III
(5
/)
(),
:, -
2,67 0,24 %,
-1,75 0,15% ( > 0,05).
1.
in vitro
( )
.~t~~.
40
1,210,11
20
1,75 0,15
20
10
20
nn .
no (
< 0,05).
no nn (
<
0,05).
10
/,
30-40 %
< 0,025).
/.
()
4,67 0,2%,
3,0 0,3 % ( < 0,05).
(50
/)
10
, .
, ,
50
5-10 /
. 10-
(50
/)
8 . 18 [7].
50
100
, . .
100
500
8.
in vitro
,
1 n
40 ,
1,1
XJ1
2,08 0,13
34,08 2,66'
16,92 1,42"
10
1,83 0,09'
45,63 4,30
24,07 1,36'
54,08 6,54
26,20
:~'~iJ~~::'~~jt~,:.
11,
50
2,42 0,22'
<
0,05) .
3,
140
120
100
""~
!;! 80
"'
")
60
-;:::
)
40
10
-+-
50 /
.-
50
1 /
__... 5 /
10 /
. 18.
....,._
50 /.
5 / (67,95 5,04 ).
(5-10
/).
< 0,05).
50 / (54,08 6,54 ;
(20-40 ).
(5-10
/) ,
().
10
(31,11
41,07
vitro
50 /).
26,2
1
/
in
Staphylococcus aureus.
..
/ (
, ,
vivo
[52].
< 0,01).
, . ,
, -Ig-,
,
IgG-
Ig
[48, 49].
-Ig-
IgG- ,
, ,
-Ig-.
(-1370),
[19, 38).
[38).
100 / [38).
III ,
(1-250 /),
- ;
N-,
-1,
in vitro.
. .
().
[34, 43].
III
: -, -
-6, -10.
1{3,
, ,
> 0,05).
N(2)-
38
c-jun
p65-NFB . ,
(:
NFB (
). ,
4,32 0,84 ,
51,32 8,3 ,
( < 0,05).
) (-
[15].
11,87 0,91
17.
[7]
III
..
(.
9 . 20).
- .
19, :
350%
300%
250%
200%
150%
100%
50%
0%
:i:
:;
s
:i:
"'L..
< "'
:;
s
s"'
:[ :;
"'-
.e.IC)
-8-ll'>
;:
"'L..
< "'
s :;
:;
s
s"'
:[ :;
-8-"'
--~
--~
~:;
:3-
::::
"'L..
s :;
::::
::::
"'L..
. 19.
::::
9.
,
2,21
40,40 7,89.
17,73 1,24
1t,14':f'i~i'
24,91 6,07
4~.~~. :7,,.
( )
4,32 1,76
~~~~~~~1.s~l(r..
,
. .5",~ :r;J~~rti
1,83 0,19
:'t~~~Hl:.J:Q,i!.;rcjt.
,
..i,Q.$,.;t .~.:
2,79 0,56
10
:~~!!f/.~~l(~:... . ....
1,6s.oi~
2,01
11
51,32 17,42
SO
45,63 9,03
11,87 1,91
~!,2Q. 7!?$:;
24,07 2,86.
3;t.o~.:t;.~.s~ .
52,12 14,47
1.,r9i:!::.2,~3.
52;30 12,37
.:M,11.:tl~t9'
67,95 10,58
41,07 11,os
< 0,05).
16,71 3,95"
350%
300%
250%
200%
150%
150%
100%
100%
50%
50%
0%
0%
..
~
ro
ro
:r
i:; .
"" L-
ro
""
:s; :::;
a.i::::
1- Q)
.
i::::
~
-......
Q)
::r
:r
::.:: <')
. 20.
() (6)
40 /.
-,
NK-
(),
[1, 7).
70 %,
.10.
IgG, IgM
IgA
CD4
(-),
),
CD21
CD3
CD8
(-),
(-
(-)
CDllb
86,8 :!:: 3,08 /
(94,45 3,02 vs
),
-2
(4,371,17 vs
-
11
~.
10.
(%)
9,80 1,30
:2);ot::t,,;:1~ 1
3,70 1,57
1;.s :t o:s1..
tb~,(~~~~lifji.:~)a ~~~'
CDSO (I-3- LFA-1)
i;JPSP~t~~~~Q~~~;14~~~;ta~6!{~j};~~~~~;:;;i:~:;:,:: .:~::;;i:::;{>.
CD71
(DeuenoD )
2,38 0,83
.....~:~~~~:~:1~~j; :~ : ..
32,05 4,15
CD95 ( AP0-1/Fas)
.~"li:~~~fa11~~1i.~):..
HLA-DR
5,60 1,60
,141. ;~:d;~q
71,10 2,40
~ 1~,jJ':~:1,ss
lgM
12,60 4,90
18,60 4,19
i,34>q~s1J
1,to ~ 0:;25
1,80 0,30
1,42 0,30
<.i~;1t :t:2,~
19,99 2,38
.; 1.:5~ ;i; q,0:1
1,60 0,30
CD21 ( -r1>1)
~Dt~:(t.l1t~11":r)r
CD16
(F-n)
c0:t6(~~~~p~.~~~~~'*::':o.:;:::::
CD11 (r -1) 11
.t~b;~~~rP~:~iti,;1~~a:~~~ :.;;::
CD25 ( -2)
:(i:~~A:~~i-nitr~~~i~~~~Af~Jl:~~~~~.:~, . . :I~:;:.:::~::.~;~:. ~:
CD71
( ) n
0~;ioi 4.$6
CD95
( nn
AP0-1/Fas)
4,30
9~ .t: 2,30~
22,60
ai~_,~f~~~~~~) :
lgG
1SJ~\
lgM . _
___
1,BO:t:0,30
1,90+0,46
1,90::0,46
CD95,
(39,68 5,73 vs
22 4,38 % ).
3,5
, .
3 ,
CD95.
10 9/, :
- 65,8%, - 27,5%,
- 3,2 /.
6,5 0,43
3,5
2 /
30
10-14-
- .
CD8- N-.
N-, F-
. , ,
( -1),
CD95 (
3 )
CDllb
2,6 )
(32,38 4,33 vs
< 0,05).
2 .
86,8 3,8 %
-2
30
3-5
. 10-14-
-,
. , -
, ,
66,1+5,1 %,
. .
< 0,05).
(66,6 4,2 %;
-,
(37,14,9%).
,
.
N-.
. ,
. ,
CD71,
2,5
CD95,
III
Haemophilus influenza, lebsiella, Escherichia
coli, Proteus mirabllis, III
L-DR-, , -
bacteriaceae,
Entero-
- -
: 5. aureus
,
5. pneumoniae,
. faecalis,
fluenzae, (
,
),
in-
1.
. aeruginosa.
2.
3.
4.
5.
7.
, .
Ig--
2005; 7: 233-236.
..
2007: 77-83.
. .
: . .:
,
8.
2006.
..
),
.., ..,
: ,
( ,
..
. .
. .
6.
),
.., ..,
. . .
NK,
. . .
2000; 1: 18-21.
..
.. .
".
..
/3-, ,
2004.
. . "
..
IV .
2003; 48(7): 5-11.
. .
9.
.., ..
iotic
-: :
:
. , ..
/3-
4.1.
Streptomyces cattleya,
/3-,
-,
[8, 24,
/3-
27].
,
,
:
(.
11).
(, , )
/)-,
, ,
[13].
11.
8~n
n/n
[40],
[2, 9].
-. , ,
-1,
-1
, m-
[40, 61].
. ,
-1,
--,
11).
/)-,
(. .
[61].
[2, 23].
Acinetobacter
baumannii
- [21].
(
r-)
Staphylococcus spp.
Streptococcus pyogenes
Streptoooccus pneumoniae
Enterococcus spp.
. :
Neisseria spp.
r :
Clostridium spp. ( . difficile)
: acteroides spp.
:
Haemophylus spp.
E.coli
Proteus spp.
Klebsiella spp.
Enterobacter spp.
Citrobacter spp.
Morganella spp.
Serracia spp.
:
. aeruginosa
.11.
(.
21),
),
,
[40].
Neisseria, Haemophilus,
[59].
, ,
Strepfococcus
faecium, Pseudomonas cepacia, Pseudomonas ma/tophilia, Pseudomonas aeruginosa [22,
33]. ,
-, . .
AmpC.
Enferococcus spp.,
Pseudomonas aeruginosa
, -
3,
, 3-
40, 61].
[40].
, ,
Pseudomonas aeruginosa
[11, 36].
: /3-:,
Streptococcus pneumoniae
/3-: ,
/3-
[18].
[2, 4].
:,
:,
/3-: [61]. :
) /
[39].
: :
[40, 56].
12.
, 3
[3, 7].
[40],
[23].
, /3-,
[2]
, :
[2].
1-3 /
~u11
12.
n ; ;
, .
23];
, r
Enterobacteriaceae;
[15, 40, 60, 61],
, ,
~~:;i~t
n /s; ,05- , 1 / s
n ; ;
0,3 r 2
[53]
/, /; 1-2 r
2- 3 ; .1 70 - 80 %;
,
_ 5 ..,. % , .5
5 60 14 3 22 231
11 spp.;
11,. / s1e
11,
-; ,
:~:.~~1~~:~//\~
30 [58)
[60]
aerugmosa,
, , , ,
11
n , ,
; . ,
[22].
50 %
[2].
/,
,
-
,
Candida afblcans,
, ,
/3-
. Nl
[23].
Sato .
, .
[49]
[14].
-.
NI.U. Rahman,
4.1.
. Nlazumde
[44]
-2
L-
(. .
20).
N-
[12].
(.
22).
, . .
[45-47, 50].
Staphylococcus
aureus
[54].
[59].
(LTB 4)
-: [50].
[20],
J.
Gutieez Fenandez
. -
()
+--
LJ
~*~**,.
1$$"
. . -
N-
~
"
..
"
". .
v
-2--+- ~i
LAK
~~
"" "~
.it""
~!.
"
----------~--------------ii;;;;;---- ,
. . -
" ; ; _
;;;;-..
.,,..
()
........
!!!!!!!!!!!!!!!!,...~ ,
- - -
""""
. 22. n n
, Escherichia coli,
Serratia marcescens, Klebsie/la pneumoniae, Salmone//a typhimurium
[54].
- .
[48].
Candida alblcans
[43].
coli,
IgG. IgG-
(30].
co/i
[6].
, -
[19].
N-
-2-
. Otega .
[42] ,
L-.
, ,
,8-
N-.
,8-,
, -
, -
11
,8-
1.
..,
..
2008; 20:
39-45.
2.
:
. . ..
, .. , .. . .:
,
3.
2000.
..
. . . .
.. /3-
. . .
. .
5.
2005; 7: 233-236.
.., ..
. . .
. 2002; 4(2): 46-47.
6. Adino/fi L.E., Utili R., Dilillo . et /. Intracellular activity of cefamandole and aztreonam against phagocytosed Escherichia coli
and Staphylococcus aureus. J. Antimicrob.
Chemother. 1989; 24: 927-935.
7. Baldwin .., Lyseng-Williamson ..,
S.J. Meropenem: review of its use in
the treatment of serious bacterial infections.
Drugs 2008; 68: 803-838.
8. Birnbaum J., Kahan F.M., Kropp ., MacDonald J.S. Carbapenems, new class of beta-lactam antiblotics. Discovery and development of imipenem/cilastatin. Am. J. Med.
1985; 78: 3-21.
9. Bustamente ./., Drusano G.L., Tatem ..,
Standiford .. Postantiblotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1984; 26: 678-682.
10. Car/one N.A., Cuffini .., Tullio V., Cavallo G. Carbapenems and potential immunomodulating properties. ln: lmmunotherapy
of infections. Ed. .N. Masihi. New York:
Marcel Dekker, 1994: 167-176.
11. Chen . ., Livermore D.M. In vitro acti\ity
of iapenem, compared with imipenem and
meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J. Antimicrob. Chemother. 1994; 33: 949-958.
21. Gur ., Korten V., Unal 5. et /. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (-23
and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY
Program sites. J. Med. Microiol. 2008; 57:
1529-1532.
22. Hellinger W.C., Brewer N.S. Imipenem.
Clin. Proc. 1991; 66: 1074-1081.
23. Hellinger W.C., Brewer N.5. Carbapenems and
monobactams: imipenem, meropenem, and aztreonam. Clin. Proc. 1999; 74: 420-434.
24. Kahan F.M" Kropp " 5undelof J.G" Birnbaum J. Thienamycin: development of imipenen-cilastatin. J. Antimicrob. Chemother.
1983; 12: 1-35.
25. lkawa " Morikawa N" lkeda . et /. Population pharmacokinetics and pharmacodynamics of iapenem in paediatric patients. J.
Clin. Pharm. Ther. 2008; 33: 203-210.
26. 5.J. Doripenem: review of its use in
the treatment of bacterial infections. Drugs
200~68:2021-205~
" Gerckens L., 5unde/of J.G., Kahan F.M. Antibacterial activity of imipenem:
27. Kropp
antiiotic.
Rev. Infect.
54.
55.
56.
57.
58.
59.
60.
61.
. , ..
[51].
-
(,
, ),
5.1.
, ,
- (
-)
Staphylococcus aureus
Staphylococcus epidermidis,
11
Ala.
D-Ala-D-
13.
13.
[2, 3]
ca/is . faecium), (
( ,
-),
),
5. pyo-
( .
fae-
difficile).
(.
23)
[64, 65].
5. aureus
-
5.aureus
-
5. epidermidis
5treptococcus spp. (
-)
5treptococcus pneumoniae
: Clostridium spp.
( . difficile)
: Listeria spp.
Corynebacterium spp.
5. aureus
Enterococcus faecalis
Enterococcus faecium
-
Aspergillus flavus
Fusarium verticillioides
. 23.
);
/3-
lococcus aureus,
30
Staphy-
[65].
[2, 64].
[55].
[12, 36].
1980-
[45],
[5, 31].
Clostridium diffici/e,
[31, 46].
[15].
[66].
--
[2, 3].
[51].
; ,
1000
/3- ;
, --
Streptococcus pneumoniae
[37].
--
[41].
[42, 70].
[6].
[2].
(LY333328)
Eli Lilly [65].
< 1
/),
[27].
5 %
[18].
[56].
(1397)
40926.
, ,
, . . Haemophilus influen-
, .
zae,
[9].
Streptococcus
- Staphylococcus
[4].
Enterococcus
aureus
[25, 61].
[4].
[64].
, -
[58, 64).
Sfaphylococcus
aureus
Sfaphylo-
coccus aureus,
(,
[58].
2003
[32].
[3, 51].
Enferococcus
, ,
2006
[13, 39].
13
Baci//us sui/is
[63],
[19).
, ,
, .
Aspergil/us
verficillioides [59].
11
[2].
Staphy/ococcus aureus
(-,
,
-)
[16].
(7].
, ,
5.1. r
, ,
S. aureus
[17).
,
,
14
, -
, . .
11
(65].
G2
(21,9 vs 13,9%),
, , ,
(68].
, ,
, ,
, -
ii
14.
0,25 4 1
2 ; ;
n - 55 % [3]
[54]; ,
[5, 31]; ,
(. . -), . faecium,
Clostridium difficile,
S. viridans, S. bovis,
dilficile ( l'!,
, n n)
'
/;
4-8 / :
/;
-,_,~,'''
"',
'~'
,,
''
",,'~
~7,'
''
"
6%;
1 ;
; - 93 % [47]
7,5-15
'
[67]
, -
Sfaphylococcus aureus
( . . -,
-}
[7, 17]
blcans,
Candida al
(.
24).
.
.
,
, ,
[50].
. -
Candida alblcans
()
()
()
.14.
-.
Candida a/blcans
[8].
[20).
in vivo
. ,
D- ,
[33].
dida a/blcans
Can-
Candida alblcans,
[53].
30
[62].
50
/.
Candida alblcans
lococcus aureus
Sfaphy-
[28].
. ,
[44).
Ig-
[54].
[10];
11
[48).
"
2.
.. " . . .
..
.
RGD:
2004.
2005; 100(4-
5): 44-49.
3.
." ..
, .
, -
Staphylococcus aureus
::;
:
,
5. aureus
,
.
:
, ,
.
:
.
:,
1.
..
r
, -
11
11
.. , .
[44].
6.1.
Pseudomonas aeruginosa,
Acinetobacfer baumannii,
Enferobacferiace-
ae
fi-,
, Bacillus /.
. ( )
()
, ,
, -
. (-
, -
- ()
[37].
- -
Bl
2, -
1943
[5].
[33].
() -
30
[1].
., -
.. .. -
[25].
. -
(,
[6].
[48, 54],
, -
, -
(.
.va<.
11
[6, 8].
G-8. [2].
Baci//us brevis
25) [32],
r al'loJB(lJ-;f.fl E:fnJ!feeEr:oJJ;blialc()ffe[rJHsfp,Jp.,
Pseudomonas aerugino-
Escherichia coli
Salmonella spp.
Shigella spp. Klebsiella spp.
Enterobacter spp.
Pasteurella spp.
Haemophi/us influenzae
Acinetobacter spp.
Pseudomonas aeruginosa
Bacteroides spp.
Fusobacterium spp.
------
Clostridium spp.
Bacillus spp.
: Staphylococcus spp.
Streptococcus spp.
. 25. (
)
. .
. ,
Salmone/la
spp.
17, 34].
Pseudomonas aeruginosa
Acinetobacter baumannii [10, 33, 36, 46],
[22],
[14],
[15, 23],
. .
[19,
28, 51].
[15,
23,49].
, 60-
..
[18].
(1990- )
11
[8].
[2, 7]. ,
(. .
25).
, ,
4-
( ), -
[6].
(5].
15.
15.
( ,
, /;
2-4 / 2
1 / 4 ; 1
[1, 3, 24, 38, 40, 47]
, .
n-
.
n ,
n) [5, 6, 13,
[16...,18, 34]
, r, ,
1,5
[8]
); -
,
.
[34];
[1].
2 %
[33, 55].
(1 ],
[11, 20],
[3].
[9].
. 1990-
,
0,05
(.
[4, 8].
2004
26).
(2%
, ,
1,5
[27].
[39].
, , .
). ,
(,
[6].
/)-,
[12, 26].
. , , (
. .
, , -
[21].
:s:
:t:
~:
t--()
~ ~
tl)
~-&
<11CO>-u
.::;:
:t: JS ::;: :1'
. m :s:
.::; :s:
! :t:
:s:
i:::~~t:;
.::; s
<::
t-s
"'
..
>. <::
<::
tua.5:s:
.
:;-
:s:
~ t;
:i:
~~3J:iie
: 8. 1&:s:
~:;>Qj -8- >- <::
:s:
t--
>o>::S:: :I: :$
<:[ .
Q)
i3 ~ ~ 8
>:s: ~ ~
:s:
:t:
13 .::;
1-
25
:s:::;: ~ ~
ffi ~ gj
:ii :1'
:s:
:t:
s :t:
:s:
:t: m"'
m s
10
t-- :S:
gg
8.:s:
<::
-1 ~
16.
, ,
[29].
, ,
- -6,
-1,8
[35].
[50].
[45].
[56].
, . ,
[30].
- -
-,
..
[53].
[41-43].
11
50, 10, 2, 1
0,5
/)
11-13
27).
(.
CD4
CD8
IgG IgM,
. melaninogenica, F. necroforum, . naeslundii, S. intermedius, 5. sanguis,
5. aureus [8].
) (.
0,5
28).
18-20 %
(.
16).
95-97 %
40
(.
17).
60 37
-7 %,
6.3.
-4%,
10-
40 %.
100-
(2-4 %).
in vitro
:, .
1,8
- ,
.. .
1/200,
(100 /)
(1/2, 1/10, 1/50, 1/100
0,5 /.
40~~~~~~~~~~~~~~~~~~~~~~~~~-
35_J_~--~~----~----,~~~~~~~~~~~~~~~~~~
+-~---"-~-=---~~~~'---~~~~~~~~~~~~~~~-<
'
25_J_~~~~~~~~~~,~~~~~~~~~~~~~~--i
'
20+-~~~~~~~~~~~,~~~~~~~--~~~~~-<
'
151~=====::::::::::::=:::::'::::-::::-:::=-~:;:;;:::;::-::::-::::::::---1
10-'-~~.~~~~~~~~~~~~~~~~~~~--~--1
5-1----~~~~~~~~~~~~~~~~--~~~~~~~
.<--~~~~~~~~~~~~~~~~~~~~~~~~~
1/10
1/2
- - -
- -
. 17.
90
70
60
50
- - - - - _,,....,._ - - - -
~~
40
-~
30
20
10
. 18.
- - -
1/10
1/2
- -
.. 16.
XJ'I rn ( 8},
n ----.-....
~
in vifro
12,10 :t 1,96
68,19 11,82
: ;:
;.q.~ *:"t~:
100 r
5,21 1,05
::1~Q:J'*:;;111:
6,01
44,88 8,70
:~.~:.~:~.:~i~;;\t~~~;.~f:~ji~::~~~:)~;1~~.iQ;~t:.
10
11,38 7,03"'
1.1}6"
s,90 2,08
38,66 6,80
.~~~...~~::~~i:,;;::::.: '::tf;.~1:~:iJ:~.ilt~::::::~.~:~.6~i8
12,s
1.s
s,6:~
.!.1.2"
s,2
< 0,05).
< 0,05).
n (
1,5
.
-
0,033%
(
),
, ,
n 17.
in vifro 40
< 0,05).
0,033%
, ,
'
, ,
1.
:
. . ..
, .. , .. . .:
Pseudomonas aeruginosa
Acinetobacfer baumannii,
2.
. "
3.
2000.
..
1952.
..
: . .. ". . .
" 2001.
::
4.
.., ..,
.., ..
5.
-. .
..,
..
16.
. . .
2003;
17.
48(12): 29-32.
6.
..
7.
18.
. . ..
, .. , ..
. .
8.
2. ., 1961: 1061-1071.
..
19.
- : . ....
- . . .,
9.
1992.
..
20.
: . .:
, 2006.
10. Aoki N., Tateda ., ikuchi . et /. Efficacy
of colistin comblnation therapy in mouse
model of pneumonia caused multidrugresistant Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2009; 63: 534-542.
11. Alothman G.A., ., Alsaadi .. et /.
Bronchial constriction and inhaled colistin in
cystic fibrosis. Chest 2005; 127: 522-529.
12. Anisimov .., Dentovskaya S.V., itaeva
G.M. et /. Intraspecies and temperaturedependent variations in susceptibllity of
Yersinia pestis to the bactericidal action of
serum and to polymyxin . Infect. Immun.
2005; 73(11): 7324-7331.
13. Benedict R.G., Langlykke A.F. Antiblotic activity of Bacillus polymyxa. J. Bacteriol. 1947; 54: 24-25.
14. Champ/in F.R., Gillelamd .., Conad R.S.
Conversion of phospholipids to free fatty acids in response to acquisition of polymyxin
resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1983; 24: 5-9.
15. Conrad R.S., Galanos . Fatty acid alterations and polymyxin inding lipopoly-
21.
22.
23.
24.
25.
Jimenez-Valera
. Immuomodulatio
.5.,
Barone
the
Atimicrob. Agets
ifectios
J. et
/. I
tios
1964;270:394-39~
J. Ocul.
44. Mogi
.,
myxis:
..,
traveous colisti
al
38.
1011.
37. Li J., Nation R.L., Turnidge J.D. et /. Colisti: the re-emergig atiblotic for multidrug-resistat gram-egative bacterial i
fectios. Lacet Ifect. Dis. 2006; 6: 589-601.
11
53. Tamura ., Nagano . Modulation polymyxin of the effects of interferon on human myelogenous leukemia cells. Microblol.
Immunol. 1994; 38: 407-411.
54. Warren H.S., Kania S.A., Siber G.R. Binding
and neutralization of bacterial lipopolysaccharide colistin nonapeptide. Antimicrob.
Agents Chemother. 1985; 28: 107-112.
55. Wolinsky ., Hines J.O. Neurotoxic and
nephrotoxic effects of colistin in patients
with renal disease. N. Engl. J. Med. 1972; 266:
759-762.
56. Yeh .., Chao S.C., Chang .. Lipopolysaccharide inding and antibacterial activities of
synthetic peptide representing amino acids
90-101 of bactericidal/permeability-increasing protein. Zhonghua Min Guo Wei Sheng Wu
Ji Mian Yi Xue Za Zhi. 1994; 27: 120-132.
. , ..
1954
Streptomyces nodosum (
),
40- .
),
(),
).
Strepfoverticillium mycohepfinicum
Strepfomyces noursei (
. (
(.
18).
1956
.).
,
,
18.
1"11
( ).
nn
, -
, -
in vifro
, . -
, . .
(.
29).
, ,
, ,
().
(, , )
spp.
Candida
[11].
), ( ,
).
( Trichophyfon,
Microsporum Epidermophyton), Pseudoallescheria boydi . [1, 2, 4, 5].
[17],
19
Histoplasma capsulatum
Cryptococcus neoformans
Coccidioides spp.
Blastomyces spp.
Aspergus spp. .
:
Candida spp.
:
Leishmania spp.,
. . :
Entamoeba spp.
Acantamoeba spp.
Neggleria spp.
:
Trichomonas vaginalis
.
11
19.
19.
1 ,
, , ,
/;
1-2
, , ,
n,
1 . t ;
w, , ,
, 1 ,
, ;
500
[1, 3}
0,4-0,6
(200 000-300 ) 2
[1, 2]
N. fowleri[1,
5, 7,
, ,
[1, 3}
: ,
, ,
, , ,
, , . [t r
21
, n
, , n,
, , n,
. i1 :
w, , ,
, ,
N. (owleri.
[4, 5]
[9, 10], ,
/ ,
[4, 5].
, ,
, .
[22, 31].
,
,
(ABLC; Abelcet),
(ABCD; Amphotec
Amphocil),
(AmBisome). ,
(),
-, -
. ,
/,
[24].
[7, 28].
[12].
7.2.
[11].
[7].
, ,
(.
30).
1970-
. ,
TLR2
MyD88
CD14
NFB
[26].
. ,
, .
-,
-1~, -6,
-
, NO,
11
11
:z:
w
:s:
i::::;
i::::
L-
----
30.
n n
-2
: -
-1/3
[22].
L-.
[23].
, ,
-/3
. ,
[24].
-1, -
[20, 21].
, ,
-,
()
[15, 16].
[14-16, 20].
-, -
[17].
[14].
, .
[16].
-,
, ,
[12].
[25].
, ,
-,
. ,
-.
, -
11
4.
5.
..
, , ,
,
),
, , ,
.
-
,
-.
1.
. . ..
. .: ,
2.
2002: 57-59.
.., . .
.
: ,
3.
1980: 76.
..
. .,
1986.
2003;
5(4): 342-353.
. . . .
.., ..
. .
11
cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with new amphotericin
formulation. Antimicrob. Agents Chemother.
2006; 50: 1195-1201.
25. Sarthou ., Primi D., Cazenave .. cell
triggering properties of nontoxic derivative of amphotericin . J. Immunol. 1986; 137:
2156-2161.
26. Sau ., Mambula S.5., Latz . et /. The antifungal drug amphotericin promotes inflammatory cytokine release Toll-like
receptor- and CD14-dependent mechanism.
J. Biol. Chem. 2003; 278: 37561-37568.
27. Shadkchan ., Keisari ., Segal . Cytokines
in mice treated with amphotericin B-intralipid. Med. Mycol. 2004; 42: 123-128.
28. 5imitsopoulou ., Roi/ides ., Dofis J. et /.
Differential Expression of Cytokines and
Chemokines in Human Monocytes Induced
Lipid Formulations of Amphotericin .
Antimicrob. Agents Chemother. 2005; 49:
1397-1403.
29. 5tein S.H., Little J.R., Little .. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin
in inbred mouse strains. Cell Immunol. 1987;
105: 99-109.
30. Tokuda ., Tsuji ., Yamazaki . et /. Augmentation of murine tumor necrosis factor
production amphotericin in vitro and in
vivo. Antimicrob. Agents Chemother. 1993;
37: 2228-2230.
31. Vonk A.G., Netea M.G., Denecker N.E. et
/. Modulation of the pro- and anti-inflammatory cytokine balance amphotericin .
J. Antimicrob. Chemother. 1998; 42: 469-474.
32. Wo/f J.E., Stein 5.., Little .. et /. Amphotericin selectively stimulates macrophages from high responder mouse strains.
Immunopharmacol. Immunotoxicol. 1991;
13: 221-235.
33. Yamaguchi ., S., Tokuda . Immunomodulating activity of antifungal drugs. Ann.
N.Y. Acad. Sci. 1993; 685: 447-457.
. , ..
(,
),
15-20
S,
SV.
[2, 10].
()
Fusidium coccineum
[2, 10].
60-
[1 ].
8.1.
Streptomyces
mediterranei.
SV.
70-
11
, ,
S [1, 4, 33].
[2].
(.
20.
31).
1t1:.1~1
10.
SV, -
trachomafis,
Legionella
pneu-
S
SV
, . .
Bacteroides fragilis.
Staphylococcus spp. ( . .
-),
Strepfococ-
, .
, -
Enterococcus spp.
Bordetel/a pertussis
:
Bacteroides fragilis
Staphylococcus spp.,
..
Streptococcus spp.
Moraxella cathrrhalis
Neisseria spp.
Clostridium spp.
:
Mycobacterium tuberculosis
Mycobacterium avium
Mycobacterium leprae
Chlamydia spp.
Rickettsia typhi
Brucella spp.
Fransicella tularensis
Legionella pneumophila
n
Bacillus anthracis
11. 31.
:
, ,
Mycobacterium tu-
, ,
berculosis ,
. avium-intra-
cellulare [4].
, . . ,
Staphylococcus
aureus
[13, 15].
[1, 33].
spp., Clostridium,
Streptococcus Enterococcus
Mycobacferium fuberculosis,
(25-40 /)
( . avium-intracellulare,
.
fortuitum).
[38].
[1).
G,
[26].
47% [28].
-,
[21].
21
11.
, ,
- (, . .
, /;
2-3
0,25
; .
, , ,
); ; ,
[2]
[2, 10
n,
-
; ;
0,3 1
; ,
[1]
, -
;
(25-40 %)
. tuberculosis, i1
, ;
), ,
0,01-0,015 / f
[1, 4]
; (
);
(1:, .4]
, /,
(, , , ,
[1,
0,5 2-3 ;
1 ;
[29,
; -
) {25,
38]
[3].
[1).
-
, -
, ,
11
. /
. ,
Staphylococcus aureus
in vitro [32],
8.2.
[6, 19],
40]. ,
(.
32),
SV)
[3, 40].
SV,
[35].
, -
, -
31.
..........".~ ,
[5]
.
-
1/3
[12].
-6
-10
[43].
[20].
[13]. ,
- -
-2
[23].
, ,
. .
[40]
[22].
[6].
Bendtzen . [7],
. -1 1
in vitro,
/,
15-50
- -6.
[41].
, ,
- -2
-
5-15
/.
-1 -6
-.
, ,
[9],
[16].
Targowski [37].
1978 .
[14].
. ,
, -
1990
,
- ,
.
.
(
)
: , ,
, ,
;
, ,
.
1.
. . ..
r, .. , .. . .:
,
2.
2000.
..
.
3.
.., ..,
..
. .
.
4.
..,
..,
.., ..
5. Amurrio ., Lewden S., Nicolas R. ef /. Effect of treatment with clindamycin, erythromycin, rifamycin or gentamicin on the ingestion capacity of peritoneal macrophages
in mice. Pathol. Biol. (Paris) 1990; 38: 13-18.
6. Bellahsene ., Forsgren . Effect of fusidic
acid on the immune response in mice. Infect.
Immun. 1980; 29: 873-878.
7. Bendfzen ., Diamanf ., Faber V. Fusidic acid, an immunosuppressive drug with
functions similar to cyclosporin . Cytokine
1990; 2: 423-429.
8. Bersani ., Berfoleffi R., / M.L. ef
/. In vitro and vivo influence of rifamycins on human phagocytes. Chemioterapia
1987; 6: 420-425.
9. Bobadil/a-Gonzalez ., Garcia-Menaya J.M.,
Cordobes-Duran . ef /. Generalized urticaria to fusidic acid. Allergy 2009; 64: 817-818.
10. Brufani . Anzamicins. In: Topics in antii
otics chemistry. New York, 1977; 1: 91-212.
11. Chrisfiansen . Fusidic acid adverse drug reactions. Int. J. Antimicrob. Agents 1999; 12: 3-9.
12. Chrisfiansen . Fusidic acid non-antibacterial activity. Int. J. Antimicrob. Agents 1999;
12: 73-78.
13. Collignon ., Turnidge J. Fusidic acid in vitro activity. Int. J. Antimicrob. Agents 1999;
12: 45-58.
14. Casfro Marfinez F.J., Ruiz F.J., Tornero
. ef /. Systemic contact dermatitis due to
fusidic acid. Contact. Dermat. 2006; 54: 169.
15. Delgado ., Zaman S" Mufhaiyan . ef /.
The fusidic acid stimulon of Staphylococcus
aureus. J. Antimicrob. Chemother. 2008; 62:
1207-1214.
16. Doric ., Abram ., Rukavina . Antimicroial activity and immunological side effects
of different antiiotics. Folia Biol. (Praha)
1993; 39: 162-165.
17. El-KassarN., KalfonP., Fromonf P. efa/. Fusidic
acid induced acute immunologic thrombocytopenia. Br. J. Haematol. 1996; 93: 427-431.
18. Forsgren . Antimicroial agents and host
defence. Scand. J. Infect. Dis. Suppl. 1984; 43:
24-33.
11
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
. , .. , ..
. .. -
1952
-D-
).
, -
, -
(1944) -
9.1.
Actinomyces (,
, .),
(,
Micromono-
spora ( .), ,
10
[5].
[37, 38].
() 2--
, /3-.
(.
22).
1n
11
111 n
1~ n:,
, . .
( . .
[5],
16S.
33.
III
[1].
spp. .),
(Pseudomo-
1)
30S-
2)
30S-
Pseudo-
3)
[43,
54).
, ,
[5).
cobacferium
tuberculosis
My-
[3].
Yersin-
,
, ,
, -
, -
r--t--{
. :
Mycobacterium tuberculosis
Mycobacterium avium
Mycobacterium spp.
Nocardia spp.
r---+-......,f---- Listeria monocytogenes
.------lf---+--
Francisella tularensis
Brucella spp.
:
. coli
Proteus spp.
lebsiella spp.
Enterybacter spp.
Serracia spp.
:
Pseudomonas aeruginosa
Acinetobacter spp.
Flavlmonas oryzihabltans
-
33.
(Pseudomonas aeruginosa,
Klebsiella spp., Escherichia coli .) Mycobacterium tuberculosis.
Micobacterium avium
[1, 56].
. ,
Pseudomonas aeruginosa,
, . .
70 %
[39, 40].
um tuberculosis,
9, 14].
[6, 8,
Mycobacteri-
, . .
[39, 40].
,
,
IV
, -
Pseudomonas aeruginosa.
[1].
. ,
[30].
Pseudomonas aerugi-
nosa
[60].
. -
Pseudomonas aeruginosa
Escherichia coli.
, ,
. ,
[37].
(0-
0-
. ,
, N-)
[38, 39].
(6')-(2"),
[19].
-. ,
[57].
, . .
[52, 64].
/3-
[33].
Staphylococcus aureus,
Enterobacteriaceae
Pseudomonas aeruginosa [29).
, . .
[61].
/3-
9.2.
,
, , . .
, . ,
/3-,
mexicana,
Leishmania
{-
[42].
. 23
[28].
L-
, , ,
-1 t-trns-
, -
au.1111t113.
11 (. . ),
, , , , , ,
1 ,
::.;:
[7, 32]
; - (, , ,
); 11 (, ,
, /;
8-12 4
- 84 %;
.); ;
; 1 ,
[7, 32)
- (, , , ; ;
); (, , );
10% [15]
[7, 15]
~.,~~-1~'~':!8~~~
CXCR4 -
CD4
[23, 25].
9.3.
.
.
, ,
, :
[11].
(, ,
, )
-:
in vitro
, ,
,
Candida alblcans
-:
[67].
:t::
:s:
::1
111
:.:
:s:
~
<
-,
. .
(66].
(49]
Miyata,
Shinohara
1 / ,
10 /
100
[69].
(.
34).
()
11
'
'~
~;;;;;;;;;;;;;;_,........."il ;'\
11
11
11
111
-----
. 34.
.....,....,,...~ ,
, ,
[2].
[11 ].
in vitro.
[68].
[35, 36).
IgM-
IgG-
(,
[59).
),
[12].
[2].
- -,
[58).
-2
..
[38].
- -,
in vitro
[50].
, ,
(),
. ,
, ,
, .
Ig-
[34].
. ,
Thl/Th2
Th2
[51, 65].
1.
. . ..
, .. , .. . .:
2.
2000.
.., ..,
.. .
( .)
3.
III
. . .
5.
www.
rlsnet.ru/articles_ 44 7.htm.
1998.
.., ..
6.
7.
..
()
-
..
(USP DI),
3.
. .: ,
., -
).
. .
(, , ,
4.
tuberculosis:
, ,
1991;
.., ..
36(2): 27-29.
. . .
..
.. . : ,
2007:
88-94.
8.
..
. . . .
.
9.
..
: .... -
. . ,
10.
2004.
..
.. . .: ,
2003: 102-
111, 495-513.
11.
.., ..
. . . .
1998;
61(3): 50-53.
12.
..,
..,
.., ..
. . .
1999; 44(2):
29-32.
13.
.., ..,
.. .
. .
.
14.
1991; 7: 43-46.
.., ..,
.. .
aeruginosa,
Pseudomonas
. . . .
.
15.
..
.
. . .
.
16.
.., ..
. .: ,
17.
..,
2003.
..
18.
Aderson
39.
40.
41.
42.
43.
44.
45.
otics on mitogen responsiveness of lymphocytes and interleukin-2 production. Chemioterapia 1988; 7: 369-372.
Jana S., Deb J.K. Molecular targets for design of novel inhibltors to circumvent aminoglycoside resistance. Curr. Drug Targets
2005; 6: 353-361.
Jana S., Deb J.K. Molecular understanding of aminoglycoside action and resistance.
Appl. Microblol. Biotechnol. 2006; 70: 140150.
Labro .-. Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or Immuno-Fairy Tales?
Clin. Microblol. Rev. 2000; 13: 615-650.
Leibovici L., Vidal L., / . Aminoglycoside drugs in clinical practice: an evidencebased approach. J. Antimicrob. Chemother.
2009; 63: 246-251.
Lejkowicz F., Belavsky L., Kudinsky R.,
Gery R. Bacteraemia and sinusitis due to
Flavimonas oryzihabltans infection. Scand.
J. Infect. Dis. 2003; 35: 411-414.
Lenoir G., Anfypkin Y.G., Miano . ef /. Efficacy, safety, and local pharmacokinetics
of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized
with Pseudomonas aeruginosa. Paediatr.
Drugs 2007; 9: 11-20.
Mayer . . Review of epidemic aminoglycoside resistance worldwide. . J. Med. 1986;
80: 56-64.
46. Maldonado P.D., Barrera D., Medina-Campos O.N. et /. Aged garlic extract attenuates gentamicin induced renal damage and
oxidative stress in rats. Life Sci. 2003; 73:
2543-2556.
47. Mandell L.A. Effects of antimicroblal and
antineoplastic drugs on the phagocytic and
microblcidal function of the polymorphonuclear leukocyte. Rev. Infect. Dis. 1982; 4:
683-697.
48. Mendez-Tovar L.J., Serrano-Jaen L., Almeida-Arvizu V.M. Comblned cefotaxime and amikacin for immunomodulation in
the treatment of actinomycetoma resistant
to conventional treatment. Gac. Med. .
1999; 135: 517-521.
Microiol.
Im-
10
..
10.1.
Streptomyces aureofaciens,
1948 .
1950 .
(),
Streptomyces rimosus.
, ,
[4].
[3],
4- ,
(.
24).
~ 14.
nnn1
r (n n)
cafarrhalis,
, .
, ( . py-
lori), , ,
( ),
, , ,
70S [3].
laid-
influenzae, . ducreyi,
[1, 25].
lawii
..
[1],
( .
lg .
acnes,
(.
35),
dif-
ficile), , ,
. ..
[23]
Debrah
200
6 .
5. pyogenes,
50 /
70 /
, ,
:
pneumoiae
Streptococcus
Neisseria meningitides
Moraxel/a catharrhalis
______
'""'
Haemophy/us influenzae
Yersinia spp.
Vibrio cholerae
:
Chlamydia spp.
Micoplasma spp.
Rickettsia spp.
-:
Enterobacteriaceae
:
Enterococcus faecalis
Enterococcus faecium
Staphy/ococcus aureus
11.
Borrelia spp.
Leptospira spp.
:
35.
Treponema spp.
Rickettsia spp.
Plasmodium falciparum
I
1
),
, , .
. ,
(), ,
S.E.
Ganer .
[34)
,
,
, . . .
, ,
[5].
[26].
, ,
, , (
, .).
, ).
, , ,
. ,
, . .
. ,
. /
tro
[4].
70S-
vi-
(Staphylococcus aureus,
Enterococcus spp. .) .
G.G. Zhanel
[94, 95]
[5, 26].
in vifro
25.
. . -
Sfaphylo-
um,
, ,
coccus aureus,
/3-
Enterobacteriaceae,
Profeus
[16].
15.
n , n
;
n
6 ;
0,3-0,5 r
25-40%
, 6n, 1,
nn, , ,
, , , ,
, , ~,
[5]
, 1
; 0,2 /
1-2 : I
- 25-40%;
- 93 %;
- 80-90% [4, 5)
[5, 31
, 1>1
, , ,
nn, , ,
, 1, , ,
, 1 , ,
n1
; , , ,
;
2 ;
,
0,05-0, 1
[5, 27]
, , ,
; , ,
, , , ;
,
/;
50-100
2 ;
- 59%, - 2540%; 71-89% [5]
, - n 6
, n
, -
n, ,
Acinetobacter spp.
{. . ),
S.
[13, 14].
, ) ;
) .
, -
, ,
W.A. Kues
[4].
[58]
in vifro. in vivo
- .
10.1.
J774
[22].
6--4-
(-3,
(.
36).
COL-3).
, .
-3. ,
[53, 54].
[24, 47].
..
Iwasaki
[45, 46]
- .
[54],
in vivo,
in vifro.
.-------------FADD
:
:
------------
,'1:
.
:~
-----
j
i
-9 )
.
-3
,
36.
-9.
, -3
10
50
10-50
/.
24- .
-2.7 RF--
397
in vifro,
NS
/.
(-2)
50
, .
Onoda
[69]
-2-
()
()
-2
J.
Rudne
[74].
1)
2)
- ,
FDD-
4)
-8. ,
3)
[51]. D. Leppert
-8,
Bid,
[61]
, ,
- ,
. ,
-9. ,
Bak
Bcl-2 .
Bid,
, -
Bcl-2
RIL-
Bcl-2
Jurkat-eax
V.W. Yong
[91, 92]
, . .
().
, ,
, -
[18].
ado
[65],
L.S. Mach-
S.G. Holmes
[42],
. ,
-2 -9
(-3)
(-8)
45
in vitro.
, .
[56, 65].
Pasternak . [70]
130
J. Feuilard
[30]
. ,
J.R. Henriksen
[40]
-,
. ,
(tetO)
[90].
11
J.T. Bettany
, , -
, tt-
. ,
90 %)
[41, 75].
[29]
-.
. ,
D. Favre
(SIVmac),
--,
nef,
pSIVmac Delta
(pTet)
(. 37).
, . .
U-.
, ,
HeLa.
[6, 17].
-.
N.S. Zeidner
[93],
.
::
". 37. ,
, (
43 % .
),
, .
80-
Z. Khadzieva
[2].
[50]
2,5 . (
15 ). T.N. Savitskaia [78],
, ,
[72].
- ,
. :
14-19-
(.
38).
, ,
[66]
R.F. Massung
[87, 88],
- ,
Anaplasma phagocytophilum.
, -
J.D. Walters
, -
- , ,
. ,
)~ ~
..
gt:
ro
t:
t:
tl:
s s
~~
>-
-&
sI
><:{
I
t:;
<:{ ID
s
!;<
ro
. 38.
J.C. Hoyt
[43],
iNS-
NO,
. ,
. , ,
S.. Agawal .
NFB -1
-.
(7]
- 0,04 % .
, iNS-
iNS-,
38
NFB,
(NO)
(iNOS)
38 ,
N-
NO,
A.R. Amin
(10, 11]
50 %,
38
iNOS.
, ,
38 .
NO iNOS.
Akamatsu
[8],
iNOS
NO
, N-
n
[33],
, ,
. ,
( 2 0 2 ), ()
(0 2 -),
, N-,
-2, -
, :
(NO). -
15-30 / 50 %
[48].
. -
[7].
[47],
Jain
. ,
. /
vitro ,
) .
, ),
35,8-58,3 /.
(,
Ingman
.
.
[44]
[85] ,
Suomalainen
.
.
[79]
L. Shapira
in vivo
in vifro,
( ,
), N-
-2
NO
14-
(19].
, ,
NO
, -1.
Solomon . (82]
-1.
, -
NO
-lj)
, .
, , ,
in vivo
J..
(80].
Akunda . [9]
-.
NO N-
. ,
(21].
in vivo
in vitro.
2 (2)
in vivo,
, , ,
NO
2, . .
NO
2- . -
, ,
/1-,
/1-
, ,
SAP
Clq.
[84].
-.
SAP, Clq,
/1-.
- , . .
-.
, -
[96].
-.
Zhao
, -
-1/1,
.
.
.
[27, 28],
Familian
Lee
[60].
. ,
. Nualat .
[68].
N-
. ,
H.L.
CD4/CD8,
R.S. Kalish,
Ehrlichia canis.
S. Koujak [49].
, -
[39]
-.
(,1-,4 /),
10-
~- /.
, . . ,
in vitro
-.
, (
[55].
Ig-
(1-5
/)
IgE.
IgE
-4-
Blimp-1
mad-4,
1 J-
-.
[38).
, --
Ig-
-,
. .
Sandler
[76, 77]
8301.
. ,
- .
- .
..
Klebsiella pneumoniae
Smith-Norowitz . [81]
- -
Ig-
, .:
AdTetIFN
-10
NO
[73] ,
-,
S. Ruan
-,
, l-
. ,
-10
CCR5 CXCR3,
F. Giuliani
[36, 37],
-10.
F. Giuliani
[36]
-/3
),
-, -
-fi,
-,
-/3
( CD40 CD40L) .
-fi, -,
- h2-
,
--
hl-, . .
, .
, -
[63].
39
---
39.
(....... ,
;; ;;
. catarrhalis.
, (
), ,
1.
, , ,
, ,
.
Acholeplasma laidlawii
. .
.., ..,
..
2.
.., ..,
, , ,
..
, , ,
, .
3.
4.
6.
7.
8.
,
.
-,
,
.
::
.., ..
: ,
5.
..
. .,
1988;
33(10): 767-771.
, , ,
. . .
9.
1998.
.., ..
. Consilium Medicum 2009; 11(4).
., Furukawa 5., Takayama 5. et /.
Drug-induced hepatitis with autoimmune
features during minocycline therapy. Intern.
Med. 2003; 42: 48-52.
Ahmed W., Rahmani ., Dent ., Granf
5. The cyclin-dependent kinase inhibltor
p21(CIP1/WAF1) ocks paclitaxel-induced
G2M arrest and attenuates mitochondrial
injury and apoptosis in p53-null human leukemia cells. Cell Cycle 2004; 3: 130.
Agarwal 5.., Tewari ., Banerjee G.
study on transferae R-plasmids among
Shigella species at Lucknow. J. Commun.
Dis. 1997; 29: 351-354.
Akamafsu ., Asada ., Komura J. ef /. Effect of doxycycline on the generation of reactive oxygen species: possie mechanism
of action of acne therapy with doxycycline.
Acta Derm. Venereol. 1992; 72: 178-179.
10. Akunda J.K., Johnson ., Ahrens F.A., Kramer . . Chlortetracycline modulates acute
phase response of vivo perfused pig livers, and inhiblts TNF-alpha secretion iso-
lated Kupffer cells. Comp. Immunol. Microiol. Infect. Dis. 2001; 24: 81-89.
11. AminA.R., AffurM.G., Thakker G.D. efal.
novel mechanism of action of tetracyclines:
effects on nitric oxide synthases. Proc. Natl.
Acad. Sci. USA 1996; 93: 14014-14019.
12. Amin A.R., Pafel R.N., Thakker G.D. ef /.
Post-transcriptional regulation of inducie nitric oxide synthase mRNA in murine
macrophages doxycycline and chemically modified tetracyclines. FEBS Lett. 1997;
410: 259-264.
13. Affur M.G., Patel R.N., Patel P.D. ef /. Tetracycline up-regulates -2 expression
and prostaglandin 2 production independent of its effect on nitric oxide. J. Immunol.
1999; 162: 3160-3167.
14. /.. Regulatory role of osteogenic
growth peptide in proliferation, osteogenesis, and hemopoiesis. Clin. Orthop. Relat. Res.
1995; 313: 64-68.
15. Basakcilardan-Kabakci 5., Thompson .,
Carfmell ., Le Corre . Adsorption and
precipitation of tetracycline with struvite.
Water Environ. Res. 2007; 79: 2551-2556.
16. Berger 5.. The use of antimicroblal agents
for noninfectious diseases. Rev. Infect. Dis.
1985; 7: 357-367.
17. Berman ., Perez .., Zell D. Update on
rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc.) 2007; 43: 27-34.
18. Beffany J. ., Peef N.M., Wolowacz R.G. ef
/. Tetracyclines induce apoptosis in osteoclasts. Bone 2000; 27: 75-80.
19. Beffany 1. ., Wolowacz R.G. Tetracycline
derivatives induce apoptosis selectively in
cultured monocytes and macrophages but
not in mesenchymal cells. Adv. Dent. Res.
1998; 12: 136-143.
20. Borg R., Dofevall L., Hagberg L. ef /. Intravenous ceftriaxone compared with oral
doxycycline for the treatment of Lyme neuroborreliosis. Scand. J. Infect. Dis. 2005; 37:
449-454.
21. Cosenfino ., Pifea D., Moro G. ef /. The
anti-fibrillogenic activity of tetracyclines on
PrP 106-126: 3D-QSAR study. J. Mol. Model. 2008; 14: 987-994.
22. D'Agosfino ., Arcoleo F., Barbera . ef /.
Tetracycline inhiblts the nitric oxide syn-
thase activity induced endotoxin in cultured murine macrophages. Eur. J. Pharmacol. 1998; 346: 283-290.
23. D'Agosfino ., Ferlazzo V., Milano 5. ef /.
Chemically modified tetracyclines induce
cytotoxic effects against J774 tumour cell
line activating the apoptotic pathway. Int.
Immunopharmacol. 2003; 3: 63-73.
24. Debrah . ., Mand 5., 5pecht 5. ef /. Doxycycline reduces plasma VEGF-C/sVEGFR-3
and improves pathology in lymphatic filariasis. PLoS Pathog. 2006; 2: 92.
25. De/ Rosso J.Q., Websfer G.F., Jackson . ef
/. Two randomized phase III clinical trials
evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J. Am. Acad. Dermatol. 2007; 56: 791-802.
26. Dizer ., Hayaf L., Beker .. ef /. The effect of the doxycycline-rifampicin and levamisole comblnation on lymphocyte subgroups and functions of phagocytic cells in
patients with chronic brucellosis. Chemotherapy 2005; 51: 27-31.
27. Doan T.L., Fung .., Mehta D., Riska P.F.
Tigecycline: glycylcycline antimicroblal
agent. Clin. Ther. 2006; 28: 1079-1106.
28. Familian ., Boshuizen R.5., Eikelenboom .,
Veerhuis R. Inhibltory effect of minocycline
on amyloid beta fibril formation and human
microglial activation. Glia. 2006; 53: 233-240.
29. Familian ., Eikelenboom ., Veerhuis R.
Minocycline does not affect amyloid beta
phagocytosis human microglial cells.
Neurosci. Lett. 2007; 416: 87-91.
30. Favre D., Blouin V., Provosf N. ef /. Lack
of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated
transgene expression in nonhuman primates
after intramuscular injection of recomblnant adeno-associated virus. J. Virol. 2002;
76: 11605-11611.
31. Feuillard J., Korndoerfer ., 5chlee . ef /.
Stringent doxycycline-dependent control of
gene activities using an episomal one-vector
system. Nucleic Acids Res. 2005; 33: 137.
32. Forloni G., lussich 5., Awan . ef /. Tetracyclines affect prion infectivity. Proc. Natl.
Acad. Sci. USA 2002; 99: 10849-10854.
54.
logical parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology 1996; 31: 163-169.
56. Kloppenburg ., Verweij C.L., Miltenburg
.. ef /. The influence of tetracyclines on
cell activation. Clin. . Immunol. 1995; 102:
635-641.
57. Kozak ., Ergul ., Hess .. ef /. Delayed minocycline inhiits ischemia-activated matrix
metalloproteinases 2 and 9 after experimental
stroke. Neurosci. 2006; 7: 56.
58. Kremlev S.G., Roberfs R.L., Palmer . Minocycline modulates chemokine receptors but not
interleukin-10 mRNA expression in hypoxicischemic neonatal rat brain. J. Neurosci. Res.
2007; 85: 2450-2459.
59. Kues W.A., Schwinzer R., Wirfh . ef /. Epigenetic silencing and tissue independent expression of novel tetracycline induci!e system in dou!e-transgenic pigs. FASEB J. 2006;
20: 1200-1202.
60. Kuzin /./., Snyder J.E" Ugine G.D. ef /. Tetracyclines inhiit activated cell function. Int.
Immunol. 2001; 13: 921-931.
61. Lee C.Z., J.S., Huang . ef /. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J.
Cereb. Blood Flow Metab. 2006; 26:1157-1164.
62. Lepperf ., Lindberg R.L" Kappos L., Leib S.L.
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis
and bacterial meningitis. Brain Res. Rev. 2001;
36: 249-257.
63. Liu J" Kuszynski .., Baxfer . . Doxycycline
induces Fas/Fas ligand-mediated apoptosis in
Jurkat lymphocytes. Biochem. Biophys. Res.
Commun. 1999; 260: 562-567.
64. Lokeshwar B.L., Escafel ., Zhu . Cytotoxic activity and inhiition of tumor cell invasion
derivatives of chemically modified tetracy-
87.
88.
89.
90.
91.
92. Yong V. W.
Immue-mediated eurodege
eratio d europrotectio i
MS.
It.
MS J.
93. Yong V.W" WellsJ., GiulianiF. efa/. Thepromise of miocycline i eurology. Lacet Neurol.
2004; 3: 744-751.
94. Zeidner N.S., Brandf K.S., Dadey . ef /. Sustaied-release formulatio of doxycyclie hyclate for prophylaxis of tick ite ifectio i
murie model of Lyme borreliosis. Atimicrob.
Agets Chemother. 2004; 48: 2697-2699.
95. Zhane/ G.G., Homenuik ., Nichol . ef /. The
glycylcyclies: comparative review with the
tetracyclies. Drugs 2004; 64: 63-88.
96. Zhane/ G.G., Karlowsky J.A., Rublnsfein .,
D.J. Tygecycline - the new glycylcyclie
atiblotic. . Rev. Antilfect. Ther. 2006; 4:
9-25.
97. Zhao ., Ling Z., Newman .8. ef /. TNFalpha kockout d miocycline treatment
atteuates ood-brai barrier leakage i
MPTP-treated mice. Neuroiol. Dis. 2007; 26:
36-46.
11
.. , .
Staphylococcus
aureus
, ,
[1].
11.1. r
[33].
[1].
. ,
, , ,
[13].
(-
-).
tridium difficile
[23].
(,
, ,
).
(,
[1, 28].
(.
40),
[1].
parum, ,
. ,
[35, 37].
[29].
. ,
[20].
Clos-
. :
Staphylococcus aureus
Streptococcus pyogenes
Streptococcus pneumoniae
: Peptococcus spp.
Peptostreptococcus spp.
' - - - - + 1
Fusobacterium spp.
Bacteroides spp.
: Clostridium spp.
( Clostridium difficile)
:
Toxoplasma godii
Plasmodium falciparum
Pneumocystis carinii
Eimeria pragensis
Babesia gibsoni
.
40.
16.
1 , 1
, ,
,
11; ,
, s/, /, , !"l,
;
0,5-0,6
, , ,
, ( 11),
[1]
, 1
, ,
(,
, , )
-,
t~n , , ;
, /, /;
0,15-0,45 3-4
; s/ - , 2
; / - , 3-1 ,2
10-45 ;
[1]
, ,
,
, 11 ( ,
), n1 [1, 23,
Staphylococcus aureus
[1, 26].
[21],
11.1.
5. au-
reus [14].
24
[17].
. ,
14- ,
()
,
r
:r
:s:
::r
:s:
~:s:
~
"
"
. 41.
(~ ,
!! !! !! !! "
Escherichia coli
coccus aureus
7-
28- , 42-
7-.
[19).
Staphylo-
(.
41).
[36).
, )
. ,
(.
, .
thefaiotaomicron
fragilis)
[30).
Staphylococcus aureus,
),
vitro [9].
in
[8, 15].
Legionella pneumophila
, -
2-10
[11].
100
[24, 27].
[35].
cus aureus
(32].
IgG
3, ,
[25].
24
[31].
(.
42),
N-
[17].
N-
[18].
Staphylococ-
-2
(31].
in vifro
3-
[25].
[33].
, -
IgG (FcyR),
(CD3)
in vitro
in vivo
, -
CD4
, -
Th1/h2
h1
42_
11
CD4
[22].
[37].
80-
- ,
-,
Thl,
Acfinobacil/us
actinomycefemcomi-
..
[2, 5, 7].
- .
27.
23
95-97 %.
60
40
2,19-5,12%,
- 2,7-4,54 /, 2,5-5,6 / (. 27).
in vitro 40
l'lpenapa
1 (
[3, 4].
15-46
),
1,5
), .
(.
50 100 /. ,
28).
1,2
).
50
/ -
28.
n/n
-
nt
:!:: ~),
! ~r:r
54,068,15"
4,30 2,71'
14, 18 15,29*"
; -
in vitro
n
v
23
< 0,05).
< 0,05).
, ,
2,4 , - 1,9 .
5 (2- )
21 % .
25,5
(23
4-10
18
20-30%,
(1- )
(.
66,1 /.
19.
29,
43).
.
n/
-
11,887,53"
; -
98,58 11,21
1~~$~;':!1)19~;
.. ;. :j;"jj ":"\:1;53~ .
5,82 0,72"
< 0,05).
< 0,05) .
5
5
. 43.
0%
20%
40%
60%
80%
f::il
111
CI
, . .
23
..
. -
[5],
, ,
6.
. .
N-, -.
7.
.., ..,
.. .
1991; 7: 43-46.
..
- : . ....
,
.
1.
:
. . ..
, .. , .. . .:
,
2.
2000.
.., .., ..
. -
, .
. .
3.
4.
..,
..
1980; 10, .
No 722214 (1979).
.., .., ..
.
5.
. ,
1998: 127-130.
..
:
. .... . . . .,
2001.
- . . ., 1992.
8. Amurrio ., Lewden 5" Nicolas R. ef /. Effect of treatment with clindamycin, erythromycin, rifamycin or gentamicin on the ingestion capacity of peritoneal macophages
in mice. Pathol. Biol. (Paris) 1990; 38: 13-18.
9. Asfry C.L., Ne/son 5., Karam G.H., 5ummer
W.R. Interactions of clindamycin with antibacterial defenses of the lung. Am. Rev.
Respir. Dis. 1987; 135: 1015-1019.
10. Baker .1., Wilson .. Effect of clindamycin on neutrophil killing of gram-negative
periodontal bacteria. Antimicrob. Agents
Chemother. 1988; 32: 1521-1527.
11. Bhardwaj N., Horwifz .. Interferon-gamma and antiiotics fail to act synergistically to kill Legionella pneumophila in human
monocytes. J. Interferon Res. 1988; 8: 283293.
12. Borrmann 5., Lundgren /., Oyakhirome 5.
ef /. Fosmidomycin plus Clindamycin for
Treatment of Pediatric Patients Aged 1to14
Years with Plasmodium falciparum Malaria. Antimicrob. Agents Chemother. 2006; 50:
2713-2718.
13. Burga/efa ., Velasco G.L., Pelefier R. ef /.
The effect of clindamycin on intraphagocytic Staphylococcus aureus in leukocytes from
patients with chronic osteomyelitis. Enferm.
Infec. Microiol. Clin. 1992; 10: 143-147.
14. Chaleva ./., Vasileva /. V., 5avova M.D. Absorption of lincomycin through the respiratory pathways and its influence on alveolar
macrophages after aerosol administration to
chickens. Res. Vet. Sci. 1994; 57: 245-247.
15. de Fijfer C.W., Verbrugh .., Heezius
.. ef /. Effect of clindamycin on the intracellular bactericidaJ capacity of human
peritoneal macrophages. J. Antimicrob. Chemother. 1990; 26: 525-532 .
ed dogs experimentally infected with Babesia gibsoni. J. Vet. Med. Sci. 2003; 65:
579-584.
38. Yunus ., Horii ., Makimura 5., Smifh A.L.
The relationship between the anticoccid-
ial effects of clindamycin and the development of immunity in the Eimeria pragensis/mouse model of large intestinal
coccidiosis. J. Vet. Med. Sci. 2005; 67: 165170.
. , .. , .. , ..
1952
.,
(15-
),
14-
, ,
50S- .
30),
14-
14-, 15-
16- (.
16-
, , , -
30.
[12)
n (s)
()
{nn)
n (n)
(,
()
n)
(n)
()
:
n
. .
),
(,
),
[43,
(, ,
)
16-
16-
46].
15-
Enterobacteriaceae,
Pseudomonas Acinetobacter
[5].
14-
()
, 16-
(.
44),
Sfrepfo-
, . .
, ,
, , , ,
, , .
14-
15-
31
(-
Staphylococcus
aureus
Streptococcus
Peptostreptococcus Campylobact
spp.
er spp.
Helicobacter
Peptococcus spp.
Propioibacterium
pylori
pyogees
Listeria spp.
Micobacterium
avium
Streptococcus
Coriebacterim
peumoiae
diphtheriae
Bacteroides spp.
Toxoplasma
godii
Legioella
spp.
Haemophylus
Cryptosporidium
spp.
Moraksella spp.
Neisseria
ifluezae
oorrhoeae
. 44.
Chlamydia spp.
Micoplasma spp.
Ureaplasma spp.
. -
. -
450,
[7, 16].
, -
( , ,
),
[16].
1u'1131.
n , , ,
,
,
(7)
"~~:~;t;;;~~j=to;15
;
0,25-0,5 1 ;
4,5 %, ;
- 37 %; - 50 %
, r , ,
0,4 3 ;
, w ( 5 %) -
; n 30-40%,
-
47 % [7]
, n (. . ), , , , ;
, Campylobacter spp.;
; ; , ,
, , , , , , w
46]
, ,
[9].
1-5 %,
- 5-14 % [46].
12.2.
[2, 14].
15-
(),
FK-506
[56].
68].
[15, 60,
14-
. .
(.
.
46
45.
[15].
45).
()
(-6, -8,
-),
-
nn , -
-2
NK
46.
[53].
, ,
[27].
-10
-8
-:
69],
[53,
[18].
. ,
, -
(-6, -
8,
(41].
-), ,
[63, 65];
[19, 30,
64, 65].
, ,
, ,
1- 0,
[20].
[41, 55].
[6, 28].
-, .
[54]
-2.
Morikawa
[36].
[4 7].
hl-,
(IgM) [36].
N-
[24].
(.
47).
[14]
Bacci
90- .
, ,
, ,
, (
; ,
: -
[47].
+--
,
. .
-8,
-6,
-
411!:::
14-
.....:~
" ....
......:"" ....
~~
.... ~
.....:
.....:
"
.__
16-
+--
47.
!!!!!!!!!!!!!!!!!!1811~ ,
"""". )
-1,8,
[11, 16].
, ,
[32].
[15].
, ,
. ,
( )
--
[8, 45].
14-
,
14-
[15],
[34].
(),
, : 15-
: N- [62].
. ,
[50, 58].
, :
-8
, , ,
[45].
. :
[17],
, ,
. ,
[24].
.. . [11] ,
-8 , . . -,
[33, 70],
, ()
1-
[50].
. ,
, .
: 14-
16-
(),
-,
[18].
- -6,
, ,
18, 51].
,
[16,
14-
[16].
[54].
14- ,
[35].
12.4.
-
, -
A.L.
Kozyskyj .
[44],
1995
2001
30 /.
15-
[43].
[57].
. ,
, ,
L. Richeldi
[61]
Daenas
[21],
-10,
11.5.
. ,
10
18-46
..
300 ,
0,05%
, 2 / HEPES
1 10-
/ .
, ,
30
.. , . R,
. , .
[1, 3, 4, 10].
, ..
[10],
50
0,5 106
30
50
in vitro
2,5
(.
- (
Rhone-Poulenc Rorer)
60
37
50
50
32).
1,5
0,5
/ - ,
7,4.
, -
4,5
31.
in vitro
1111
0,5
8 ,
rJJ
20,02 5,40
50,70 12,50
2,58 1,20
10
< 0,05).
10-
:::!::
< 0,05).
100-
- .
()
100, 50, 10
40
60
40
/.
0,5
in vitro
97 % (. 33).
60 37
40
-7 %,
- -4 %,
8-11 /. 10-
100-
0,5
(100
/).
/. ,
95-
(2-4%).
in vitro
(.
48-50).
, .
40.,.-~~~~~~~~~~~~~~~~~~~~~~~~~~~
35+-~~~~-~-~-~~---,~~~~~~~~~~~~~~~~~--<
30+-~~-~-~~~~~-'~,-,~~~~~~~~~~~~~~~~--1
~
'
25+-~~~~~~~~.-~~~~~~~~~~~~---/
',
~ 20t---~~~-____....-~~~,...~~------~,-----=-=-=-=-=-=-=-=;;;;;;:;;;;;-~~1
~ 15+-~-,---...-C'----~~~~~~~~-=--~---~-~-~-~-~--c-~~-~..._~~-i
:r:
10+--~~~~~~~~~~~~~~~~~~~~~~~~~~--i
(.)
5+-~~~~~~~~~~~~~~~~~~~~~~~~~~--1
0+-~~~~~~~~~~~~~~~~~~~~-,~~~~~-r
1/2
1/10
1/500
1/100
--
PJ.CC. 48.
10-~~~~~~~~~~~~~~~~~~~~~~~~~~~
~ 60
~-------------------
......___
~ 4050r=====::::;:::::======~::.==::::::~~============:::~==:=i
~ 30
:::r
20
10+-~~~~~~~~~~~~~~~~~~~~~~~~~~--1
0+--~~~~~~~~~~~~~~~~~~~~-,~~~~~-r
112
- - -
1110
1/100
11500
--
. 49.
i1
5,0
"
4,5
4,0
3,5
~ 3,0
"-....
"-.... .........
f-----
"iij 2,5
1,5
1,0
,... ....
', ....
',
cr
~2.
-- --
--- ___ .
0,5
1/2
1/10
1/100
1/500
- - -
---
11
50.
33.
in vitro 40
< 0,05).
1,8
),
0,033%
100
20 %,
30 %.
25 %
),
0,033%
. ,
(.
'"''-'J1"1ua
34.
34).
ws ,
11,30
10,44
10,27
10,65
, , .
14-
15-
, ,
15-
16-
[2, 4, 8, 10].
,
, -
(JJI
45.
: ,
46.
.., ..
.
1998.
.. .
2000;
3: 56-60.
47.
..
. .
, . .
48.
. . .
- : . ....
.. -
- . . "
49.
..,
. .
50.
..
51.
.. :
. . . .
41.
..
52.
: . .... .
. . .,
42.
2004.
53.
.., ..
-
.
. ,
43.
2007.
54.
.., ..,
..
. . .
55.
2000; 45(11):
29-30.
44.
..
. -
65.
2004; 4: 60-
2006; 8: 42-47.
.., ..
.
. . .
.
. .
40.
..,
.., ..
39.
1992.
56.
13
. , 0.. , ..
(),
Streptomyces venezuelae
[24].
50S-
(.
51),
[3].
, ,
,
, ,
.
, ,
, ,
; ,
: Escherichia coli
- - - 1 " \ :
Staphylococcus spp.
Streptococcus spp.
Salmonella spp.
Shigella spp.
lebsiella spp.
Yersinia spp.
Haemophilus influenzae
Bordetella pertussis
: Listeria spp.
Corinebacterium diphtheriae
: Neisseria s
.
Neisseria spp.
:
51.
----;1>1 :
Spirochaetaceae
Clostridium spp.
Bacillus antracis
~.---
Chlamydia spp.
Rickettsiaceae
Haemophilus influenzae.
, ,
in vitro
, ,
,
,
[35].
, ,
29],
[11,
35
[1, 2, 4].
, ,
[31, 34].
[3, 9, 20].
.,
Viso
.,
Berhanu
.,
Kerveillanf-
chloramphenicol and kitasamycin, in the chicken. Ann. Rech. Vet. 1988; 19:
259-266.
26. Madan J., Kaushik D" 5ardana 5., Mishra D.
Effect of ciprofloxacin and chloramphenicol
on humoral immune response elicited bovine albumin encapsulated in niosomes.
Xue Xue . 2007; 42: 905-910.
27. Mandal ., Halder .., Dey 5.. ef /.
Development and physical characterization of chloramphenicol loaded iodegrad
ae nanoparticles for prolonged release.
Pharmazie. 2009; 64: 445-449.
28. Miljkovic-Selimovic ., Bablc ., Kocic .,
Ristic L. Antimicroial susceptiility profiles of thermophilic campylobacters isolated from patients in the town of Nis. Vojnosanit Pregl. 2009; 66: 522-526.
29. Mulvey M.R., Boyd ." O/son .. et /.
The genetics of Salmonella genomic island 1.
Microbes. Infect. 2006; 8: 1915-1922.
30. Nara P.L" Davis L.E" Lauerman L.H. et /.
Effects of chloramphenicol on the development of immune responses to canine distemper virus in beagle pups. J. Vet. Pharmacol. Ther. 1982; 5: 177-185.
31. Nissen-Druey . Pathophysiology of aplastic anaemia. Baieres Clin. Haematol. 1989;
2: 37-49.
32. Paez P.L" Becerra .., Albesa /. Chloramphenicol-induced oxidative stress in human
neutrophils. Basic Clin. Pharmacol. Toxicol.
2008; 103: 349-353.
33. Steel " Wan " .. Single live cell
imaging of chromosomes in chloramphenicol-induced filamentous Pseudomonas aeruginosa. Biochemistry 2004; 43: 175-182.
34. Turton J.A" Fagg R., 5ones W.R. et /. Characterization of the myelotoxicity of chloramphenicol succinate in the B6C3Fl mouse. Int.
J. . Pathol. 2006; 87: 101-112.
35. Valle " Guiney D.G. Characterization of
Salmonella-induced cell death in human
macrophage-like -1 cells. Infect. Immun. 2005; 73: 2835-2840.
antiiotics,
14
.. , ..
( ,
, )
1960-
Enterobacteriaceae),
, )
. (
, ,
, ,
, ,
- , , ,
27, 42).
);
1980- ,
[1,
, :
: -
[37).
), , ,
1, 7 8 [19, 20,
(.
-.
(1
2 );
53).
-I
- ,
in vivo
FvyUo
F~OH
("N~)
("N~NJ
HN~
HN~
N--n
l_,
F~OH
("N,,U)
OYN~
F~OH
'-N=('~
H,NY
11.
53.
[37]
II-III
[5, 10,
(.
34-36, 39].
36).
[22, 23].
(.
S.. Spangler
( .. ),
, , ,
Propionibacterium acnes
, , -
[48, 49],
Closfridium spp.,
,:u 36.
in
vitro n
(Enterobacteriaceae,
. aeruginosa)
)
-
)
-
n n
n
(
4111
, .
(100%)
1-t
ll~~~~~;,;::t:~~':.:~~~
aeruginosa
H~~~~~!!l1r:1il11itX''nR
41
. (, <, )
, . . .
.
(: 90
> 4
/).
, ,
, . .
4, 6, 8, 13, 16],
, ,
6,8
5,2
(1, 2,
:90 in vifro
. (
[20).
, )
in
vitro
[7, 44].
, :
. :
, :
[7, 17].
750
, :
750
[5, 16].
. ,
III
,
,
, . .
, :
(.
, :)
III
, ,
IV
37).
/,
).
HiGlance Laboatoies
Aventis),
[5, 6, 12, 16].
:
III ,
90
III :
500
,
: ,
.,
1- 2-
(.
IV
54).
37.
61>
n
, ,
n1>1
r-
' .
.
MRSA -
S. aureus.
,
"d?
. . ,
(.
1-n-7-[(S,S)-2,8--(4..)-8-]-
-1,4--4---
54.
IV,
55) [37].
IV
. ,
IV
[27,
. . -
GD
00
Veropharm)
-
.
PJ.tc.
55.
IV
IV
320
[7]
, /3-
IV
>
>
(.
38).
[44, 49).
> >
[2, 16, 23, 28, 40).
IV
>
[39).
) .
-
Bayer
[Hinemox] HiGlance
Laboratories),
400
()
38.
[21, 23],
1,
n1
n 11
111,
11-
( Enterobacte-
riaceae)
Strep-
11
:n
nn11
14'
5-7 .
.
56
IV
medius, 5. sanguis
in vifro, in vivo
5. infer-
in vitro
41,43,44].
(5,2 /),
(3,4 /),
(3,1 /).
IV -
99
),
[2].
.--+-{
.------+-fi
( .
Enterobacteriaceae)
Mycobacterium spp.
Nocardia spp .
.--+-f---Listeria monocytogenes
(. Eterobacteriaceae),
Mycobacterium tuberculosis,
cobacterium avium
-
(. coli, Proteus
- nn
, nn
56.
14.2.
, . gingivalis, . ac-
finomycefemcomifans . forsyfhia. ,
[4,
4,
12-20.
. ,
IV
, ,
-,
( )
in vivo,
Azuma
(2001)
[24].
NO
in vitro . coli
2,5 / [51].
J.P. Wong . [57] ,
, Staphy/ococcus aureus
/), ,..
(0,05-0,25
, (
NO ( 40 /).
) , ,
, -1 -,
, , -
. -
[51].
, -
-1,
Dalhoff
I. Shalit [31].
, -2
-, -
.G.
Stunkel
[45].
. (1991)
in vitro
0,3-10
-1 ,
[46].
-1
in vitro
-2,
-1 -,
25
[25].
-10 -12.
5-
(2
IV
/)
-12 . ,
Staphylococcus infermedius,
coli
-10,
. NS-
-6 -lfi.
NO
, .
(2,5
/)
-1
[52].
, 5- (
1.
/) 24-
[31].
CD4
CDS.
D .
[57].
(45
/)
coli
[52].
, ,
[51 J.
, ,
, ,
coli [24].
NO
, -
[51, 52].
/i-
-2
[42].
in vitro in vivo
-1,
, -
, -
[46].
. ,
-1, -2 - .[51].
0,1-30
-1/3 ,
- .
-2. , -2
(.
/),
(15
(5
/), ,
(15
57).
/)
, .
-1
). ,
0,3-10 /.
1 6
15-75 / (
) 5-25 / (
-1
()
431.
-2 - ,
-1
-2,
-1
CD8.
-2 -,
--
, -1 -
-2
CD4
CD3
CD3
CD3
CD4
[46].
(-, -1,
-2, -10,
, -
-12),
-, -1,
--
-2
D,
CD4, CD8
, -
57.
(,
/ ,
(25
-2
Bacferoides fragilis.
/)
coli
CD4 ,
CD3, CD4 CD8
(80
/)
-2.
-2
, , ,
. ,
. ,
, -
[37] ,
50 / 1
40 / 2
10
L3T4
LYT2 -, -
CD8).
CD8
75
CD4
CD8,
CD4
[31].
CD4
15
. ,
, .
, NFB, -
. ,
-3',5'
1, -6
-;
-,
-2
,
,
1.
..
-,
. .
2.
IV
".
. . . " 2009.
: . .
, ,
, ,
3.
..
..,
. .:
. . . ,
80- . .. .
..,
, 25-
..
: ,
4.
1999.
.., .., .,
.. -~
. .: -
5.
2010: 427-475.
-008842/10,
. .
2009.
.,
2004.
: . .
..
". .
. . "
.., ..
. .
20.
..
. .: .
1998.
1995.
21.
..
.., ..
. . .
1998.
..
(): 10-
. .
2000; 1: 39-43.
." .., ..
:
. .: ,
2010.
.. :
.
2011; 5: 8.
.., .., ..
.
. .
. .
1997; 2: 30-35.
." ..
. .: ,
11
- . .
. .,r.
." ..
16.
".
" 2011.
19.
. .: ,
15.
..
. "
. .: ,
14.
. .
13.
: . . ".. .
12.
750
. . . .
11.
..
. .: ,
10.
9.
[Hileflox]),
8.
.., ..
7.
.., .., ..
.: ,
6.
17.
. . .. , .. .
2006.
2009; 5: 19-24.
. . 2001; 3(4).
22. Acar J.F. comparison of side effects of levofloxacin to other agents concerning the
ecological and microioloogical effects on
normal human flora. Chemotherapy 2001;
47: 15-23.
23. / .. et /. P-Lactamase productions and susceptiilities to amoxicillin,
amoxicillin-clavulanate, ticarcillin/clavulanate, cefoxitin, imipenem, and metronidasole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusabacteria from 28
U.S. centres. Antimicrob. Agents Chemother.
1990; 34: 1546-1550.
24. Azuma ., Shinohara " Wang P.L" Ohura
. Quinolones alter defense reactions mediated macrophages. Int. Immunopharmacol. 2001; 1: 179-187.
25. Barry A.L., Fuchs P.S. In vitro activities of
sparfloxacin, tosufloxacin, ciprofloxacin and
fleroxacin. Antimicrob. Agents Chemother.
1991; 35: 955-960.
26. Bertio J., Fish D. The safety profile of the fluoroquinolones. Clin. Ther. 2000; 22: 798-817.
27. Ball ., Mandell L" Patou G. et /. new respiratory fluoroquinolone, oral gemifloxa-
28.
29.
30.
31.
cin: safety profile in context. Int. J. Antimicrob. Agents 2004; 23: 421-429.
Blondeau J., Missaghi . Gemifloxacin:
new fluoroquinolone. J. . Opin. Pharmacother. 2004; 5(5): 1117-1152.
Cooper .. In vitro activity of tosufloxacin, new quinolone antibacterial agent. J.
Antimicrob. Chemother. 1992; 29: 639-647.
Dalhoff . In vitro activities of quinolones.
. Opin. Invest. Drugs 1999; 8(2): 123-137.
Dalhoff ., Shalif /. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 2003;
3(6): 359-371.
.,
,
.
, .
39
,
.
. -,
,
.
"..,"m,u" 39.
, ,
, N
, h1-
h2-, , -
(-, -,
-)
, ,
-,
1 1 -
, ,
/3-
.:
/3- ,
, ,
/3-
/3-
.: :
( -
/3-
) ,
, ;
: ,
N- (
).
, -
, -,
/3-;
, ,
/3-
Staphylococcus aureus,
/3-
40.
, ,
58
, .
-,
--
--
'
;;
:
-
13-
'
;;
s:
i(.)
5 3
;.;
s:
"'
....
:I: i::;
:I: s:
-&
:I:
'-
>-'--
"'
"'
.(.)
s:
:;; 8
CD <'>
-
(~ ,
Pj.jC.
~ )
58. -
59
, -
. ,
, -
40.
..,
.if!:..
1.pynna v
.nr
Q
.,
, ,
nnn
(____.
11.
59.
,
,
- - ~ )
. ,
. -
, -
41.
, , -n
, -n
'l'Jol,.
rn
n, , -n
, -n
..
. '
~~~~~~.~~~.J~n?.~
i1n~.1, ,
, N-, -n,
N-
-1
:~~~~~~if:;.>.:~~:.;:;:~~.::.::;~~~~~~~~.{.::;.:;::+1~1J~'*11>);:N'1t~.ner~;r;.~iJtAf1ef:i~
n
, , -n
. -
, .
-.
III
(.
60).
1-
g-~~~
ffi. :i:~ m
()
L...
~~~
s
)~-8-~~
~)~
~
[~~ . .. . ~ ~~
]i g- ~
:;; ~ -8-" I ro
((] >:S:
((] <.J :i::
Ji
1i
:i:
::I: n:I
:s:
~ :s: ::r
::
:s:"'"'
i:; ~ g
"' . 1-
)s
~~
~ ~ ~
:s:
):s: ~
:S:
"' :s:
'"
i:;
"'
()
" '"
"':s:
::;
::
<.J
'
Q)
ro -
'"-8-"'
~::; ~
::
:s:
"'i:;"'
]i ~
:i3
1- :: <.J
:s:"'"'
7 7 7
"':s: :s:
~ i::; ....
.::;
~ 8.
ffi ~
~5
1-,:s:
~ ]j
"'::
L.:.
"'<.J"'
i:;
::"'
"1 :s:
g- ~
Q\C)
-8-"'
~ ~
i::::;
: .
Q) >.
:s:"'
:1i !;;: ~ 1 ~ ::::; 2
i:;"' ::r
."'
\"'"'
:s: -8-
~~i~
,_ ,_
Q)
~,~ ~ ~ ~
::
((]
::
(')"'"'
::;
1-
1-
<.J
"'~
"'
"'
. <.J
~"'
;>,
7
:s:
(---.
11.
~ )
60.
OZON.ru
1111111111111111111111111